<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        40-972-19
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        LISONORM 10 - 5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LISINOPRIL,AMLODIPINE BESILATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10,5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        38.75
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="GEDEON RICHTER PLC." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            GEDEON RICHTER PLC.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 1916]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            AJA PHARMACEUTICAL INDUSTRIES
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            AJA PHARMACEUTICAL INDUSTRIES
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09BB03 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Lisonorm tablet is a combination product of amlodipine, which belongs to a group of medicines called calcium channel blockers, and lisinopril, which belongs to a group of medicines called angiotensin- converting enzyme (ACE) inhibitors. Lisonorm is used to treat hypertension (high blood pressure) in adults.</p><p><em>Lisonorm10 mg/5mg tablet </em>is indicated in adult patients whose blood pressure has already been controlled on the combination of 10 mg lisinopril and 5 mg amlodipine.</p><p><em>Lisonorm20 mg/10mg tablet </em>is indicated in adult patients whose blood pressure has already been controlled on the combination of 20 mg lisinopril and 10 mg amlodipine.</p><p>&nbsp;</p><p>In patients with high blood pressure amlodipine works by relaxing blood vessels, so that blood passes through them more easily. It also improves blood supply to the heart muscles. Lisinopril decreases the tightness of your blood vessels and lowers your blood pressure.</p><p>You might not have any symptoms from your too high blood pressure, but it may increase the risk of certain complications (such as stroke or heart attack), if you do not take your antihypertensive medicine regularly.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not take Lisonorm</p><p>You must not take this medicine:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to lisinopril or amlodipine or any of the other ingredients of this medicine (listed in section 6)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to other ACE inhibitors (such as enalapril, captopril and ramipril) or other calcium channel blockers (such as nifedipine, felodipine or nimodipine)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have had an angioedema (severe allergic reaction, symptoms such as itching, nettle rash, wheezing and swelling of the hands, throat, mouth or eyelids), related or not to treatment with an ACE-inhibitor</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if a family member has ever had a severe allergic reaction (hereditary angioedema) or if you</p><p>have earlier had a severe allergic reaction of an unknown cause (idiopathic angioedema)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if your blood pressure is too low (severe hypotension)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a narrowing of the aorta (aortic stenosis), of a heart valve (mitral stenosis), an increase in the thickness of the heart muscle (hypertrophic cardiomyopathy)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have circulatory failure (including shock originating in the heart called cardiogenic shock)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have suffered a heart attack (myocardial infarction) with heart failure</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are more than 3 months pregnant. (It is also better to avoid Lisonorm in early pregnancy &ndash; see section &rdquo;Pregnancy and breast-feeding&rdquo;.)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have diabetes or impaired kidney function and you are treated with a blood pressure lowering medicine containing aliskiren.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have taken or are currently taking sacubitril/valsartan, a medicine used to treat a type of long-term (chronic) heart failure in adults, as the risk of angioedema (rapid swelling under the skin in an area such as the throat) is increased.</p><p>&nbsp;</p><p>Warnings and precautions</p><p>You must tell your doctor if you think you are (or might become) pregnant. Lisonorm is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see section &rdquo;Pregnancy and breast-feeding&rdquo;).</p><p>&nbsp;</p><p>Talk to your doctor before taking Lisonorm:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have heart problems</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have problems with your blood vessels (collagen vascular disease)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have kidney problems</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have liver problems</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are undergoing a surgery (including dental surgery) or anaesthesia</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are under dialysis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are about to have a treatment called LDL apheresis for removal of cholesterol</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are older than 65 years</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are on a low-salt diet and you use potassium containing salt substitutes or supplements or have high levels of potassium in your blood(hyperkalaemia)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have diabetes mellitus</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have diarrhoea or vomiting</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are receiving desensitisation treatment to reduce allergy to bee or wasp stings</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are of black origin as ACE inhibitors may be less effective, but you may also more readily get angioedema</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking any of the following medicines used to treat high blood pressure:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an &ldquo;angiotensin II receptor blocker&rdquo; (ARBs) (also known as sartans - for example valsartan, telmisartan, irbesartan), in particular if you have diabetes-related kidney problems.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; aliskiren.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking any of the following medicines, the risk of angioedema (rapid swelling under the skin in area such as the throat) is increased:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sirolimus, everolimus, temsirolimus and other medicines belonging to the class of mTOR inhibitors (used to prevent rejection of transplanted organs and for cancer)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tissue plasminogen activator (medicines to break up blood clots), usually given in hospital</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vildagliptin, a medicine used to treat diabetes</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; racecadotril, a medicine used to treat diarrhoea</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking any medicines listed below (see section &rdquo;Other medicines and Lisonorm&rdquo;).</p><p>&nbsp;</p><p>Talk to your doctor if you develop a dry cough which is persistent for a long time after starting treatment with Lisonorm.</p><p>&nbsp;</p><p>Your doctor may check your kidney function, blood pressure, and the amount of electrolytes (e.g. potassium) in your blood at regular intervals.</p><p>&nbsp;</p><p>See also information under the heading &ldquo;Do not take Lisonorm&rdquo;.</p><p>&nbsp;</p><p>Children and adolescents</p><p>Lisonorm should not be used in children below age 18.</p><p>&nbsp;</p><p>Other medicines and Lisonorm</p><p>Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.</p><p>&nbsp;</p><p>Potassium-sparing diuretics (such as spironolactone, amiloride, triamterene, used to reduce fluid retention) and potassium supplements or potassium containing salt substitutes may only be taken together with Lisonorm under close medical supervision.</p><p>&nbsp;</p><p>Special caution is necessary when Lisonorm is taken together with the following medicines:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; water tablets called diuretics (used to reduce fluid retention)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; other medicines used to lower blood pressure(antihypertensives)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines used in the treatment of heart diseases (e.g. verapamil, diltiazem)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; non-steroidal anti-inflammatory drugs (NSAIDs) such as acetylsalicylic acid (used to treat for arthritis, muscle pains, headache, inflammation, fever)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lithium, tricyclic antidepressants, antipsychotics, used to treat mental disorders</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; insulin and oral antidiabetics</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; autonomous nervous system stimulants (sympathomimetics), such as ephedrine, phenylephrine, xylometazoline and salbutamol, used to treat congestion, cough, cold and asthma</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; immunosuppressants (used to prevent transplant rejection, e.g. corticosteroids, cytotoxic agents and antimetabolites)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allupurinol, used to treat gout</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; procainamide (used in arrhythmias)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines, which can increase the amount of potassium in your blood, such as potassium supplements (including salt substitutes), potassium-sparing diuretics and other medicines that can increase the amount of potassium in your blood (such as heparin, a medicine used to thin blood to prevent blood clots, co-trimoxazole also known as trimethoprim/sulfamethoxazole, for the treatment of infections caused by bacteria and ciclosporin, an immunosuppressant medicine used to prevent organ transplant rejection)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; simvastatin (to lower cholesterol and certain fatty substances in your blood)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; narcotics, morphine and related medicines used to treat severe pain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anticancer medicines</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anaesthetics, used in surgery or some dental procedures. Tell your doctor or dentist that you are taking Lisonorm before you are given a local or general anaesthetic, given the risk of short-term drop in blood pressure</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anticonvulsants (such as carbamazepine, phenobarbital and phenytoin), used to treat epilepsy</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; antibiotics (medicines used to treat bacterial infections), such as e.g. rifampicin, erythromycin or clarithromycin), HIV (so called protease inhibitors e.g. ritonavir, indinavir, nelfinavir) or fungal infections (e.g. ketoconazole, itraconazole)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; herbal preparations containing St. John&#39;s wort (<em>Hypericum perforatum</em>)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; gold salts, especially when given intravenously (used to treat the symptoms of rheumatoid arthritis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dantrolene (skeletal muscle relaxant, used to treat malignant hyperthermia)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tacrolimus (used to control your body&rsquo;s immune response, enabling your body to accept the transplanted organ)</p><p>The following medicines may increase the risk of angioedema (signs of angioedema include swelling of the face, lips, tongue and/or throat with difficulty in swallowing or breathing):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines to break up blood clots (tissue plasminogen activator), usually given in hospital.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines which are most often used to prevent rejection of transplanted organs and for cancer (sirolimus, everolimus, temsirolimus and other medicines belonging to the class of mTOR inhibitors). See section &ldquo;Warnings and precautions&rdquo;.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vildagliptin, used to treat diabetes.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; racecadotril used to treat diarrhoea</p><p>&nbsp;</p><p>Your doctor may need to change your dose and/or to take other precautions:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are taking an angiotensin II receptor blocker (ARB) or aliskiren (see also information under the headings &ldquo;Do not take Lisonorm&ldquo;and &ldquo;Warnings and precautions&rdquo;).</p><p>&nbsp;</p><p>Lisonorm with food, drink and alcohol</p><p>Lisonorm can be taken with or without food, but alcohol should be avoided during treatment. Grapefruit juice and grapefruit should not be consumed by people who are taking Lisonorm. This is because grapefruit and grapefruit juice can lead to an increase in the blood levels of the active ingredient amlodipine, which can cause an unpredictable increase in the blood pressure lowering effect of Lisonorm.</p><p>&nbsp;</p><p>Pregnancy and breast-feeding</p><p><em>Pregnancy</em></p><p>You must tell your doctor if you think you are (or might become) pregnant. Your doctor will normally advise you to stop taking Lisonorm before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of Lisonorm. Lisonorm is not recommended in early pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy.</p><p>&nbsp;</p><p><em>Breastfeeding</em></p><p>Amlodipine has been shown to pass into breast milk in small amounts. Tell your doctor if you are breast-feeding or about to start breast-feeding Lisonorm is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is newborn, or was born prematurely.</p><p>&nbsp;</p><p>Driving and using machines</p><p>Before you drive a vehicle, use tools or operate machines, or carry out other activities that require concentration, make sure you know how Lisonorm affects you. Lisonorm can affect your ability to drive and use machinery safely (especially at the start of the treatment). Do not drive or use machines if you notice that Lisonorm negatively affects your ability to drive or operate machines, e.g. make you feel sick, dizzy or tired, or give you a headache.</p><p>&nbsp;</p><p><strong>Lisonorm contains sodium</strong></p><p>This medicine contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per tablet, that is to say essentially &lsquo;sodium-free&rsquo;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>The recommended dose is 1 tablet Lisonorm daily. Lisonorm can be taken with or without food. Swallow each tablet whole with a drink of water. You should take your tablet at the same time each day.</p><p>&nbsp;</p><p>If you have the impression that the effect of Lisonorm is too strong or too weak, talk to your doctor or pharmacist.</p><p>&nbsp;</p><p><u>Use in children and adolescents</u></p><p>Lisonorm should not be used in children below age 18 due to lack of data on safety and efficacy.</p><p>&nbsp;</p><p><u>Elderly</u></p><p>Generally no special dosage modification is necessary above the age of 65.</p><p>&nbsp;</p><p><u>Patients with liver impairment</u></p><p>A liver disease can influence the blood level of amlodipine. In this case your doctor will advise you more frequent medical checking.</p><p>&nbsp;</p><p><u>Patients with kidney impairment</u></p><p>Your regular medical follow-up will include frequent monitoring of renal function, serum potassium and sodium levels during therapy with Lisonorm. In case of worsening of the kidney function Lisonorm will be withdrawn and replaced by the therapy with individual components adequately adjusted.</p><p>&nbsp;</p><p>If you take more Lisonorm than you should</p><p>Contact your doctor immediately or go to the casualty department of the nearest hospital.</p><p>Overdose is likely to result in very low blood pressure, which has to be closely monitored. Signs of an overdose are electrolyte imbalance, kidney failure, rapid breathing (hyperventilation), a fast heart rate, palpitations, a slow heart beat, dizziness, anxiety, cough.</p><p>You may feel lightheaded, faint or weak. If blood pressure drop is severe enough shock can occur. Your skin could feel cool and clammy and you could lose consciousness. If characteristic symptoms such as dizziness and headache occur, you should be placed lying down with the face up. Your doctor will take further measures.</p><p>Excess fluid may accumulate in your lungs (pulmonary oedema) causing shortness of breath that may develop up to 24-48 hours after intake.</p><p>&nbsp;</p><p>If you forget to take Lisonorm</p><p>Do not take a double dose to make up for a forgotten tablet, to avoid the risk of overdose. Take your next dose at the usual time.</p><p>&nbsp;</p><p>If you stop taking Lisonorm</p><p>Keep taking your tablets until your doctor tells you to stop. If you feel better, do not stop taking the tablets. If you stop them, your conditions may get worse.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>Common side effects (may affect up to 1 in 10 people):</p><p>In a clinical trial with amlodipine and lisinopril combination were: headache, cough, dizziness.</p><p>&nbsp;</p><p>Allergic (hypersensitivity) reactions may occur with the use of Lisonorm. You must stop taking Lisonorm and seek medical attention immediately if you develop any of the following symptoms of <em>angioedema</em>:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty in breathing with or without swelling of the face, lips, tongue and/or throat.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the face, lips, tongue and/or throat which may cause difficulty in swallowing.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe skin reactions including intense skin rash, hives, reddening of the skin over your whole body, severe itching, blistering, peeling and swelling of the skin, inflammation of mucous membranes (Stevens-Johnson syndrome, toxic epidermal necrolysis) or other allergic reactions.</p><p>&nbsp;</p><p>Additional side effects that have been reported with either amlodipine or lisinopril alone (the two active substances), and may also occur with Lisonorm are the following:</p><p>&nbsp;</p><p><u>Amlodipine</u></p><p>Very common side effects (may affect more than 1 in 10 people):</p><p>Swelling.</p><p>&nbsp;</p><p>Common side effects (may affect up to 1 in 10 people):</p><p>Headache, ankle swelling, muscle cramps, feeling tired, weakness, sleepiness, visual disturbances, feeling sick, indigestion, altered bowel habit (diarrhoea and constipation), dizziness, abdominal pain, palpitations (a quicker or irregular heart beat), flushing, difficulty in breathing.</p><p>Tell your doctor if these effects cause you any problems or if they last for more than one week.</p><p>&nbsp;</p><p>Uncommon side effects (may affect up to 1 in 100 people):</p><p>Skin rash, itchy skin, loss of hair, red patches on skin, skin discolouration, hives, vomiting (being sick), muscle or joint pain, back pain, chest pain, mood changes (including anxiety), depression, sleeplessness, shaking, tinnitus (ringing in the ear), irregular heartbeat (arrhythmia), hypotension (low blood pressure), cough, taste perversion, paraesthesia (numbness or tingling sensation), runny nose, frequent need to urinate at night, urination disorders, dry mouth loss of pain sensation, increased sweating, fainting, pain, malaise (feeling unwell), enlargement of breasts in men, impotence, weight increase, weight decrease.</p><p>&nbsp;</p><p>Rare side effects (may affect up to 1 in 1000 people):</p><p>Confusion.</p><p>&nbsp;</p><p>Very rare side effects (may affect up to 1 in 10 000 people):</p><p>Allergic reactions, abnormal liver function test, inflammation of the liver (hepatitis), yellowing of the skin (jaundice), decrease in the number of white blood cells and platelets in the blood, elevation of blood glucose, heart attack (myocardial infarction), severe skin reactions (nettle rash, scaly or peeling skin), severe allergic reactions accompanied with fever, red patches, joint pains and/or eye disorders (Stevens-Johnson syndrome), swelling of the lips, eyelids and genitals (Quincke&#39;s oedema), swelling or soreness of the gums, inflammation of the pancreas (pancreatitis), inflammation of the lining of the stomach (gastritis), sensitivity to light, hypertonia (increased muscle tension), peripheral neuropathy (nerve disorder causing weakness and tingling sensation), inflammation of blood vessels.</p><p>&nbsp;</p><p><strong><em>Not known (frequency cannot be estimated from the available data):</em></strong></p><p>Trembling, rigid posture, mask-like face, slow movements and a shuffling, unbalanced walk.</p><p>&nbsp;</p><p><u>Lisinopril</u></p><p>Common side effects (may affect up to 1 in 10 people):</p><p>Headache, dizziness or light-headedness especially when standing up quickly, diarrhoea, cough, vomiting, kidney problems.</p><p>&nbsp;</p><p>Uncommon side effects (may affect up to 1 in 100 people):</p><p>Mood changes, change of colour (pale blue followed by redness) and/or numbness or tingling in the fingers or toes (Raynaud phenomenon), changes in the way things taste, hallucinations (seeing or hearing things which are not real), fatigue, feeling sleepy or difficulty in going to sleep, spinning feeling (vertigo), abnormal skin sensations (as tingling or tickling or itching or burning), feeling of rapid and irregular heartbeat (palpitation), heart attack (myocardial infarction), stroke, runny nose, nausea (feeling sick), stomach pain or indigestion, impotence, tiredness, changes in the results of certain laboratory tests (that show how your kidney and liver are working), skin rash, itching, rapid heartbeat (tachycardia).</p><p>&nbsp;</p><p>Rare side effects (may affect up to 1 in 1000 people):</p><p>Angioedema (hypersensitivity reaction with sudden swelling of the lips, face and neck, and occasionally of the feet and hands; there is a higher rate of angioedema in black patients than in non- black patients). Confusion, inappropriate secretion of the antidiuretic hormone, which controls the amount of urine you excreate, acute kidney problems, kidney failure, dry mouth, hair loss, psoriasis, hives, enlargement of breasts in men. Changes in the way things smell.</p><p>Worsening of blood picture: decrease in haemoglobin and haematocrit levels. Increase in bilirubin level (bile pigment), low level of sodium in the blood.</p><p>&nbsp;</p><p>Very rare side effects (may affect up to 1 in 10 000 people):</p><p>Decrease of blood glucose (hypoglycaemia), sinus pain wheezing, inflammation of the lungs (pneumonia), yellow skin and/or eyes (jaundice), inflammation of the liver or pancreas, liver failure, severe skin disorders (symptoms of which include redness, blistering and peeling), sweating.</p><p>Reduction of urine volume (passing less water (urine) or passing no water). Oedema in the bowels. Worsening of blood count: decrease in the number of red blood cells (anaemia). Worsening of blood picture: decrease in the number of platelets in the blood (thrombocytopenia), decrease in the number of white blood cells (neutropenia, leucopenia, agranulocytosis). These problems may cause prolonged bleeding, tiredness, weakness, disease of the lymph nodes, autoimmune disorder (when your immune system produces antibodies against your own tissues). You can get infections more easily.</p><p>&nbsp;</p><p>Not known (frequency cannot be estimated from the available data):</p><p>Fainting, depression, severe allergic hypersensitivity reactions (anaphylactic/anaphylactoid reactions).</p><p>&nbsp;</p><p>Reporting of side effects</p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p>To report any side effect(s):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia:</strong></p><p>&middot; The National Pharmacovigilance Centre (NPC):</p><p>&nbsp;- SFDA Call Center: 19999</p><p>- E-mail: npc.drug@sfda.gov.sa</p><p>&nbsp;- Website: https://ade.sfda.gov.sa/</p><p><strong>&nbsp;</strong></p><p><strong>&middot;</strong><strong> Other GCC States: &nbsp;</strong></p><p>- Please contact the relevant competent authority.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date which is stated on the carton and blisters after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store in the original package in order to protect from light and moisture.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not store above 30&deg;C.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substances are lisinopril andamlodipine.</p><p>&nbsp;</p><p><em>Lisonorm10 mg/5mg tablets:</em></p><p>Each tablet contains 10 mg lisinopril (as dihydrate) and 5 mg amlodipine (as besilate).</p><p>&nbsp;</p><p><em>Lisonorm20 mg/10mg tablets:</em></p><p>Each tablet contains 20 mg lisinopril (as dihydrate) and 10 mg amlodipine (as besilate).</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are microcrystalline cellulose, sodium starch glycolate (type A) and magnesium stearate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Lisonorm10 mg/5mg tablets:
White or almost white, round, flat, bevel-edged tablet with a score line on one side and with an engraving “A+L” on the other side. Diameter: approx. 8 mm
The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses. Packs contain 30 tablets in white, PVC/PE/PVDC-aluminium blisters in a carton.
Lisonorm20 mg/10mg tablets:
White or almost white, round, biconvex tablet with engraving on one side: “CF3”, other side without engraving. Diameter approx. 11 mm.

Packs contain 30 tablets in white, PVC/PE/PVDC-aluminium blisters in a carton.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder </strong></p><p>AJA Pharmaceutical Industries Company, Ltd.</p><p>&nbsp;&nbsp;&nbsp;&nbsp; Hail Industrial City MODON, Street No 32</p><p>&nbsp;&nbsp;&nbsp;&nbsp; PO Box 6979, Hail 55414</p><p>&nbsp;&nbsp;&nbsp;&nbsp; Kingdom of Saudi Arabia.</p><p><strong>&nbsp;</strong></p><p><strong>Manufacturer:</strong></p><p><strong>&nbsp;</strong>GEDEON RICHTER PLC.</p><p>&nbsp; BUDAPEST-HUNGARY</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in July 2023
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ليزونورم هو منتج يتكون من مادتين هما &quot;أملوديبين&quot; الذي ينتمي إلى &nbsp;مجموعة من الأدوية تسمى معطلات قناة الكالسيوم. و&quot;ليزينوبريل&quot; الذي ينتمي إلى مجموعة من الأدوية تسمى معطلات انزيم تحويل انجيوتنسين (ACE).</p><p dir="RTL">ويستعمل ليزونورم لعلاج ارتفاع ضغط الدم لدى البالغين</p><p dir="RTL"><em>ليزونورم أقراص 10ملجم/5 ملجم</em>&nbsp;يعطى للبالغين الذين تمت السيطرة على ضغط دمهم المرتفع باستخدام ليزينوبريل 10ملجم جنبا إلى جنب مع أملوديبين 5ملجم</p><p dir="RTL"><em>ليزونورم أقراص 20ملجم/10ملجم</em>&nbsp;يعطى للبالغين الذين تمت السيطرة على ضغط دمهم المرتفع باستخدام ليزينوبريل 20ملجم جنبا إلى جنب مع أملوديبين 10ملجم.</p><p dir="RTL">بالنسبة للمرضى الذين يعانون من ارتفاع ضغط الدم يعمل املوديبين من خلال ارخاء (توسعة) الأوعية الدموية مما يؤدي الى تدفق الدم خلالها بسهولة اكثر. وهو أيضاً يحسن من توارد الدم إلى عضلة القلب.</p><p dir="RTL">أما ليزينوبريل فإنه يعمل على خفض التوتر في الأوعية الدموية وبالتالي يخفض ضغط الدم.</p><p dir="RTL">وقد لا تكون لديك أي أعراض من جراء ارتفاع ضغط الدم ولكنه يمكن ان يزيد من مخاطر اصابتك ببعض المضاعفات (مثل الجلطة الدماغية والنوبة القلبية) إذا لم تستعمل الأدوية الخافضة لضغط الدم بانتظام.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول ليزونورم في الحالات التالية:</strong></p><ul><li dir="RTL">إذا كانت لديك حساسية لـ &quot;ليزينوبريل&quot; أو &quot;املوديبين&quot; أو أي من مكونات هذا الدواء الأخرى (المدرجة في الفقرة رقم-6).</li><li dir="RTL">إذا كانت لديك حساسية لأي من معطلات انزيم تحويل انجيوتنسين (ACE) الأخرى (مثل نيفيديبين، فيلوديبين، نيموديبين).</li><li dir="RTL">إذا كنت تعاني من الوذمة الوعائية (وهي ردة فعلل حساسية شديدة تشمل أعراضها الحكة والطفح الجلدي وأزيز تنفسي وتورمات في اليدين والحلق والفم والجفون) سواء كانت مرتبطة او غير مرتبطة باستعمال باحد العلاجات من مجموعة معطلات انزيم تحويل انجيوتنسين (ACE).</li><li dir="RTL">إذا كان أحد أفراد الأسرة قد اصيب بردة فعل حساسية شديدة (الوذمة الوعائية الوراثية)، أو إذا كنت قد اصبت سابقاً بردة فعل حساسية شديدة (الوذمة الوعائية ذاتية العلة).</li><li dir="RTL">إذا كان لديك انخفاض شديد في ضغط الدم (انخفاض الضغط الشديد).&nbsp;</li><li dir="RTL">إذا كنت تعاني من ضيق في الشريان الأورطي (ضيق الأورطي)، او ضيق في صمام القلب (ضيق الصمام المترالي)، أو زيادة في سماكة عضلة القلب (اعتلال عضلة القلب التضخمي).</li><li dir="RTL">إذا كنت تعاني من فشل في الدورة الدموية (بما في ذلك الصدمة الناشئة من القلب والتي تسمى الصدمة القلبية).</li><li dir="RTL">إذا كنت قد أصبت بنوبة قلبية (احتشاء في عضلة القلب) مصحوبة بفشل قلبي.</li><li dir="RTL">إذا كنت حامل لأكثر من 3 شهور ، ومن الأفضل تجنب ليزونورم في فترة الحمل المبكرة (انظر الفقرة الخاصة بالحمل والرضاعة الطبيعية)</li><li dir="RTL">إذا كنت مصاباً بمرض السكري او قصور في عمل الكلى وتعالج بدواء خافض لضغط الدم يحتوي على &quot;اليسكيرين&quot;.</li><li dir="RTL">إذا كنت قد تناولت أو تتناول حاليًا ساكوبيتريل / فالسارتان ، وهو دواء يستخدم لعلاج نوع من قصور القلب (المزمن) طويل الأمد لدى البالغين ، خطر الإصابة بالوذمة الوعائية (تورم سريع تحت الجلد في منطقة مثل الحلق) قد ارتفع.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات: </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بالنسبة للنساء يتوجب على المرأة قبل البدء في تناول علاج ليزونورم ابلاغ الطبيب اذا كانت تظن انها حامل او يمكن ان تصبح حاملاً. ولا ينصح بإعطاء ليزونورم في مراحل الحمل المبكرة ويجب عدم استعماله اذا كانت فترة الحمل تزيد عن 3 شهور حيث انه قد يسبب اضرارا خطيرة للجنين اذا استعمل خلال هذه المرحلة (انظر الفقرة الخاصة بالحمل والرضاعة الطبيعية )</p><p dir="RTL"><br />ويجب ابلاغ الطبيب قبل استعمال ليزونورم في أي من الحالات التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مرض او مشاكل في القلب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل في الأوعية الدموية (مرض الكولاجين الوعائي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل بالكلى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل بالكبد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت ستخضع لعملية جراحية بما في ذلك عمليات الأسنان او ستخضع للتخدير.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تخضع لجلسات الديلزة (غسيل الكلى).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت ستخضع لجلسات العلاج المسمى &quot;ال دي ال افريزس&quot; (وهي جلسات يتم فيها فصل الكولسترول من الدم والتخلص منه)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان عمرك يزيد عن 65 سنة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتبع حمية غذائية منخفضة الملح وتستعمل بدائل الملح أو المكملات الغذائية التي تحتوي على البوتاسيوم او كان لديك ارتفاع في مستويات البوتاسيوم بالدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابا بمرض السكري.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من الإسهال أو التقيؤ.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تستعمل ادوية لتخفيف الحساسية الناتجة عن لسعات النحل او الزنابير.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان اصلك من العرق الأسود حيث ان معطلات انزيم تحويل انجيوتنسين (ACE) قد تكون اقل فعالية في خفض الضغط ولكنك قد تصبح أكثر عرضة للإصابة بالوذمة الوعائية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تستعمل أيا من الأدوية المذكورة ادناه والتي تستعمل لعلاج ارتفاع ضغط الدم:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احد معطلات مستقبلات أنزيم انجيوتنسين-2 &quot;ARBs&quot; والمعروفة أيضا باسم السارتانات (على سبيل المثال فالسارتان، تيلميسارتان، اربيسارتان) وبشكل خاص اذا كنت تعاني مشاكل في الكلى مرتبطة بمرض السكري.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اليسكيرين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أي من الأدوية التالية ، فإن خطر الإصابة بالوذمة الوعائية (انتفاخ سريع تحت الجلد في منطقة مثل الحلق) يزداد:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيروليموس ، إيفيروليموس ، تيمسيروليموس وأدوية أخرى تنتمي إلى فئة مثبطات) mTOR تستخدم لمنع رفض الأعضاء المزروعة وللسرطان(</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; منشط البلازمينوجين النسيجي (أدوية لتفتيت جلطات الدم) ، يعطى عادة في المستشفى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فيلداجليبتين ، دواء يستخدم لعلاج مرض السكري</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; راسيكادوتريل ، دواء يستخدم لعلاج الإسهال</p><p dir="RTL">إذا كنت تستعمل أياً من الأدوية المذكورة أدناه: (انظر قسم &quot;الأدوية الأخرى ليزونورم<strong> </strong>&quot;).</p><p dir="RTL">وعليك استشارة الطبيب إذا اصبت بسعال جاف يستمر لفترة طويلة بعد البدء في استعمال ليزونورم.</p><p dir="RTL">وقد يقرر الطبيب إجراء بعض الفحوصات والتحاليل على فترات منتظمة والتي تشمل وظائف الكلى وضغط الدم ونسبة املاح الدم (مثل البوتاسيوم).</p><p dir="RTL">انظر أيضاً المعلومات في الفقرة تحت عنوان &quot;لا تستعمل ليزونورم&quot;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong>:</p><p dir="RTL">يجب عدم إعطاء ليزونورم للأطفال والمراهقين (الذين تقل أعمارهم عن 18 عاماً).&nbsp; &nbsp; &nbsp;</p><p dir="RTL">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى و ليزونورم:</strong></p><p dir="RTL">يرجى استشارة الطبيب أو الصيدلي إذا كنت تستعمل او استعملت حديثا او يتوقع ان تستخدم أي أدوية أخرى.</p><p dir="RTL">ويجب عدم استخدام مدرات البول التي تحافظ على البوتاسيوم مثل سبايرونولاكتون، اميلوريد، ترايامتيرين التي تستعمل لتقليل احتباس السوائل في الجسم وكذلك مستحضرات تزويد البوتاسيوم أو بدائل الملح التي تحتوي على البوتاسيوم في آن واحد مع ليزونورم إلا تحت إشراف طبي وثيق.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ومن الضروري توخي الحذر عند استخدام ليزونورم مع أيٍ من الأدوية التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مدرات البول (التي تستخدم لتخفيض احتباس السوائل في الجسم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مستحضرات البوتاسيوم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية الأخرى التي تستخدم لخفض ضغط الدم (مضادات ارتفاع الضغط).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تستخدم لعلاج أمراض القلب (مثل فيراباميل، دلتيازيم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الإلتهاب غير الستيرويدية (NSAIDs) مثل حامض الأستيل سالساليك (الأسبرين) المستخدمة في علاج التهاب المفاصل، آلام العضلات، الالتهابات، الحمى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ليثيوم، مضادات الاكتئاب الحلقية الثلاثية، مضادات الذهان، المستخدمة لعلاج الإضطرابات العقلية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأنسولين ومضادات مرض السكري التي تؤخذ بالفم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; منشطات الجهاز العصبي الذاتي (المحفزات السمبثاوية)، مثل ايفيدرين، فينيل افرين، زايلوميتازولين، سالبيوتامول المستخدمة لعلاج الاحتقان والسعال والربو.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خافضات المناعة (التي تستخدم لمنع رفض الجسم للعضو المزروع مثل الكورتيكوستيرويدات، المواد السامة الخلوية، مضادات النواتج الأيضية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الوبيرينول المستخدم لعلاج مرض النقرس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بروكيناميد (المستخدم لعلاج نوبات عدم انتظام النبض).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي يمكن أن تزيد من كمية البوتاسيوم في الدم ، مثل مكملات البوتاسيوم (بما في ذلك بدائل الملح) ومدرات البول المستبقي للبوتاسيوم والأدوية الأخرى التي يمكن أن تزيد من كمية البوتاسيوم في الدم (مثل الهيبارين ، دواء يستخدم لمنع تخثر الدم ليمنع تجلط الدم ، الكوتريموكسازول المعروف أيضًا باسم تريميثوبريم / سلفاميثوكسازول ، لعلاج الالتهابات التي تسببها البكتيريا ، السيكلوسبورين ، وهو دواء مثبط للمناعة يستخدم لمنع رفض زرع الأعضاء)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سمفاستاتين (يستخدم لخفض الكولسترول وبعض انواع الدهون في الدم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الادوية المخدرة ، المورفين، وغيرها من العقاقير ذات الصلة التي تستخدم لتسكين الآلام الشديدة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المضادة للسرطان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ادوية التخدير المستخدمة في العمليات الجراحية وبعض عمليات الأسنان. يجب عليك ابلاغ طبيب الأسنان بأنك تستعمل ليزونورم قبل ان يعطيك أي مخدر موضعي أو عام، حيث ان ذلك قد يؤدي الى انخفاض الضغط على المدى القريب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات التشنج (مثل كاربامازيبين، فينوباربيتول، فينوتوين) التي تستخدم لعلاج الصرع).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المضادات الحيوية (الأدوية التي تستخدم لعلاج الإصابات البكتيرية ) مثل ريفامبيسين، اريرثرومايسين، كلاريثرومايسين ، او الإصابة بفيروس نقص المناعة (HIV) المسماة مثبطات انزيم البروتيز مثل ريتونافير، اندينافير، نيلفينافير) أو الإصابات الفطرية (مثل كيتوكينازول، اتراكونازول).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المستحضرات العشبية التي تحتوي على عشبة سانت جونز (هيربيكوم بيرفوراتوم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أملاح الذهب خاصة عندما تعطى بالوريد (المستخدمة لعلاج أعراض التهاب المفاصل الروماتيزمي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دانترولين (دواء يستخدم لإرخاء العضلات، فرط الحرارة او الحمى الخبيثة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تاكروليماس (المستخدم للسيطرة على الاستجابة المناعية للجسم مما يمكن الجسم من تقبل العضو المزروع).</p><p dir="RTL">الأدوية التالية قد تزيد من خطر الإصابة بالوذمة الوعائية (تشمل علامات الوذمة الوعائية تورم الوجه والشفتين واللسان و / أو الحلق مع صعوبة في البلع أو التنفس):</p><p dir="RTL">- أدوية لتفتيت جلطات الدم (منشط البلازمينوجين النسيجي) ، تعطى عادة في المستشفى.</p><p dir="RTL">- الأدوية التي تستخدم في الغالب لمنع رفض الأعضاء المزروعة وللسرطان (سيروليموس ، إيفروليموس ، تيمسيروليموس وأدوية أخرى تنتمي إلى فئة مثبطات mTOR). انظر قسم &quot;التحذيرات والاحتياطات&quot;.</p><p dir="RTL">&nbsp;- فيلداجليبتين&nbsp;، الذي يستخدم لعلاج مرض السكري.</p><p dir="RTL">&nbsp;- راسيكادوتريل يستعمل لعلاج الإسهال</p><p dir="RTL">وقد يقرر الطبيب تغيير الجرعة و/أو اتخاذ احتياطات أخرى في الحالات التالية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تستعمل مثبطات لمعطل مستقبل انجيوستين-2 (ARB) أو اليسكرين (أنظر أيضا الفقرة بعنوان &quot;لا تستعمل ليزونورم&quot; والفقرة بعنوان &quot;تحذيرات واحتياطات&quot;).</p><p dir="RTL"><br /><strong><strong>ليزونورم مع الأطعمة والمشروبات والكحول:</strong></strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن تناول ليزونورم مع الطعام او بدونه، ولكن ينبغي تجنب شرب الكحول اثناء استعمال ليزونورم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كما يجب عدم تناول عصير أو فاكهة الجريب فروت من قبل المرضى الذين يستخدمون ليزونورم، نظرا لأنها قد تؤدي إلى زيادة مستوى املوديبين النشط في الدم مما قد يؤدي إلى زيادة غير متوقعة في مفعول ليزونورم الخافض لضغط الدم.</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية :</strong></p><p dir="RTL"><u>الحمل:</u></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بالنسبة للنساء إذا كانت المرأة حاملاً أو مرضعة او تعتقد أنها حامل أو تخطط لحدوث الحمل يجب عليها استشارة الطبيب قبل استعمال هذا الدواء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وفي العادة سوف ينصح الطبيب بوقف استعمال ليزونورم قبل حدوث الحمل او فورا عند معرفة حدوث الحمل وسوف ينصح باستعمال دواء آخر بدلا من ليزونورم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ولا ينصح باستعمال ليزونورم اثناء الحمل ويجب عدم استعماله بعد الشهر الثالث من الحمل حيث انه قد يسبب اضراراً بالغة للجنين إذا استعمل بعد الشهر الثالث من الحمل.</p><p dir="RTL"><u>الرضاعة الطبيعية:</u></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجد أن أملوديبين ينتقل إلى حليب الثدي بكميات صغيرة ، يجب على المرأة إبلاغ الطبيب إذا كانت تنوي الإرضاع الطبيعي وقبل ان تبدأ الإرضاع.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا ينصح باستعمال ليزونورم للأمهات المرضعات وسوف يختار الطبيب دواءً آخر اذا رغبت المرأة في إرضاع الطفل خاصة إذا كان حديث الولادة او انه طفل خداج (مولود قبل اكتمال الحمل).</p><p dir="RTL"><br /><strong>قيادة المركبات وتشغيل الآليات:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قبل القيام قيادة المركبات أو تشغيل الآليات أو ممارسة أي عمل يتطلب التركيز يجب عليك التأكد من تأثير ليزونورم عليك. ويمكن أن يؤثر ليزونورم في قدرتك على قيادة المركبات او تشغيل الآليات(خاصة عند بدء استعمال العلاج).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وبالتالي يجب عليك الامتناع عن قيادة المركبات أو تشغيل الآليات أو ممارسة أي عمل يتطلب التركيز إذا شعرت بأن ليزنورم له تأثير سلبي على قدراتك مثل اعراض السقم، الدوار، التعب، الصداع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي </strong><strong>ليزونورم </strong><strong>على الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدواء على أقل من 1 مليمول صوديوم (23 ملجم) لكل قرص ، وهذا يعني &quot;خالٍ من الصوديوم&quot;.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب عليك دائما استعمال هذا الدواء حسب تعليمات الطبيب تماما. وإذا كنت غير متأكد فيجب عليك الإتصال بالطبيب أو الصيدلي.</p><p dir="RTL">جرعة ليزونورم الموصى بها هي قرص واحد في اليوم. ويمكن تناول ليزونورم مع الطعام أو بدونه. ويجب ابتلاع القرص كاملا مع بعض الشراب او الماء. كما يجب تناول القرص في نفس الوقت من كل يوم.</p><p dir="RTL">وإذا شعرت ان تأثير ليزونورم اقوى او اضعف من اللازم عليك المبادرة بالتحدث إلى الطبيب أو الصيدلي.</p><p dir="RTL"><u>الاستعمال لدى الأطفال والمراهقين:</u></p><p dir="RTL">يجب عدم إعطاء ليزونورم للأطفال والمراهقين الذين تقل أعمارهم عن 18 عاماً نظرا لعدم توفر معلومات عن سلامة استعماله او فعليته لدى هذه الفئة.</p><p dir="RTL"><u>الاستعمال لدى كبار السن:</u></p><p dir="RTL">بشكل عام لا يلزم إجراء تعديلات في الجرعة للمرضى الذين تزيد أعمارهم عن 65 عاماً.</p><p dir="RTL"><u>الاستعمال لدى مرضى قصور الكبد:</u></p><p dir="RTL">إن مرض الكبد يمكن أن يؤثر في مستوى املوديبين في الدم. وفي هذه الحالة ينصح الطبيب بزيادة وتيرة (معدل تكرار) إجراء الفحوصات الطبية.</p><p dir="RTL"><u>الاستعمال لدى مرضى قصور الكلى:</u></p><p dir="RTL">بالنسبة لمرضى القصور الكلوي سوف تشمل الفحوصات الطبية زيادة وتيرة اجراء تحاليل وظائف الكلى، وقياس مستويات الصوديوم والبوتاسيوم في الدم خلال فترة استعمال ليزونورم. وفي حال ازداد القصور الكلوي سوءاً فسوف يتم وقف ليزونورم واستبداله بعلاج آخر مع اجراء تعديلات بحسب حالة كل مريض على حدة.</p><p dir="RTL"><strong>إذا تناولت جرعة زائدة من ليزونورم</strong>:</p><p dir="RTL">إذا تناولت من أقراص ليزونورم زيادة عن وصفة الطبيب فيجب عليك الاتصال بالطبيب فورا. او مراجعة قسم الطوارئ في أقرب مستشفى.</p><p dir="RTL">ان زيادة الجرعة ستؤدي غالباً إلى انخفاض شديد في ضغط الدم مما يستدعي وضع المريض تحت المراقبة&nbsp; الوثيقة.</p><p dir="RTL">وتشمل علامات او اعراض زيادة الجرعة خلل في توازن ايونات (املاح)، الفشل الكلوي، تسارع التنفس، (فرط التهوية)، تسارع النبض، خفقان القلب، انخفاض او بطء النبض، الدوار، القلق، السعال.</p><p dir="RTL">وقد يشعر المريض بالخواء او الترنح او الضعف. وإذا حدث انخفاض شديد في ضغط الدم لدرجة كافية فقد تحدث الصدمة. وقد يشعر المصاب ببرودة في الجلد وقد يفقد الوعي.</p><p dir="RTL">وإذا حدثت تلك الأعراض المميزة مثل الدوار والصداع فيجب ان يوضع المصاب مستلقياً على ظهره ووجهه للأعلى وسيقوم الطبيب باتخاذ مزيد من الإجراءات العلاجية.</p><p dir="RTL">قد يتراكم السائل الزائد في رئتيك (الوذمة الرئوية) مما يسبب ضيقًا في التنفس قد يتطور حتى 24-48 ساعة بعد تناوله.</p><p dir="RTL"><strong>إذا نسيت أن تتناول ليزونورم</strong>:</p><p dir="RTL">إذا نسيت ان تتناول الجرعة المعتادة في وقتها فيجب عليك ان تأخذ الجرعة التالية في وقتها المقرر حتى تتجنب مخاطر مضاعفة الجرعة.</p><p dir="RTL"><strong>إذا توقفت عن استعمال ليزونورم</strong>:</p><p dir="RTL">يجب عليك مواصلة استعمال ليزونورم حتى يطلب منك الطبيب التوقف عنه. وإذا شعرت بتحسن فلا تتوقف عن استعمال الدواء فقد تزداد حالتك سوءا إذا توقفت عن استعمال الدواء إذا كانت لديك أي اسئلة او استفسارات حول استعمال هذا الدواء فيجب عليك استشارة الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">هذا الدواء كغيره مكن الأدوية يمكن أن يسبب بعض الآثار الجانبية مع انها لا تحدث لدى جميع الأشخاص.</p><p dir="RTL"><strong>تأثيرات شائعة (يمكن ان تصيب لغاية&nbsp; 1 من بين كل 10 اشخاص)</strong><strong>:</strong></p><p dir="RTL">في تجربة سريرية على استخدام مزيج من املوديبين وليزينوبريل كانت التأثيرات الجانبية هي: الصداع، السعال، الدوار.</p><p dir="RTL">وقد تحدث ردود فعل حساسية عند استخدام ليزونورم. ويجب التوقف عن استعمال ليزونورم والحصول على عناية طبية فوراً إذا حدثت لك أي من أعراض الوذمة الوعائية التالية:</p><p dir="RTL">&nbsp;-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التنفس يصاحبها أو لا يصاحبها تورم (انتفاخ) في الوجه والشفتين واللسان و/أو الحلق.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;تورم (انتفاخ) في الوجه والشفتين واللسان و/أو الحلق مما قد يسبب صعوبة في البلع.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;تفاعلات جلدية شديدة بما في ذلك الطفح الجلدي الشديد ، بقع مرتفعة &quot; هايفس&quot; ، واحمرار الجلد في جميع أنحاء الجسم ، والحكة الشديدة ، والتقرحات ، وتقشير وتورم الجلد ، والتهاب الأغشية المخاطية (متلازمة ستيفنز جونسون ، انحلال البشرة السام) أو تفاعلات حساسية أخرى .</p><p dir="RTL">وقد تم الإبلاغ عن تأثيرات جانبية أخرى تحدث مع املوديبين او ليزينوبريل (المادتين الفعالتين في ليزونورم) كل على حدة ، والتي قد تحدث عند استعمال ليزونورم، وهي كما يلي:</p><p dir="RTL"><strong><u>أملودبين</u></strong><strong>:</strong></p><p dir="RTL"><strong><em>تأثيرات شائعة جداً (يمكن ان تصيب ما يزيد عن&nbsp; 1 من بين كل 10 شخص)</em></strong><strong><em>:</em></strong><strong><em> </em></strong>تورم.</p><p dir="RTL"><strong><em>تأثيرات شائعة (يمكن ان تصيب لغاية&nbsp; 1 من بين كل 10 شخص)</em></strong><strong><em>:</em></strong></p><p dir="RTL">صداع، تورم الكاحل، تشنجات او تقلصات عضلية، شعور بالتعب، نعاس، اضطرابات في النظر، شعور بالسقم، عسر الهضم، تغيرات في عادات التبرز (اسهال أو إمساك)، دوار، الم في البطن، خفقان بالقلب (تسارع او عدم انتظام نبضات القلب)، احمرار الوجه، صعوبة في التنفس.</p><p dir="RTL">عليك الاتصال بالطبيب إذا حدثت لديك أي من الأعراض المذكورة أعلاه وسببت لك أي مشكلة او استمرت لمدة تزيد عن الأسبوع.</p><p dir="RTL"><strong><em>تأثيرات غير شائعة (يمكن ان تصيب لغاية&nbsp; 1 من بين كل 100 شخص)</em></strong><strong><em>:</em></strong></p><p dir="RTL">طفح جلدي، حكة بالجلد، سقوط الشعر، ظهور بقع حمراء بالجلد، تغير لون الجلد، شرى (حكة شديدة مع حرقان بالجلد)، سقم (غثيان) وتقيؤ، آلام بالعضلات والمفاصل، ألم بالظهر، الم بالصدر، تغيرات في المزاج (بما فيها القلق) اكتئاب، ارق، ارتعاش، طنين في الأذن، عدم انتظام ضربات القلب (خلل النبض)، انخفاض ضغط الدم، سعال، تغيرات في حاسة الذوق، خدر طرفي (احساس بالخدر والتنميل في الأطراف)، رشح من الأنف، تكرار الحاجة الملحة للتبول الليلي، مشاكل واضطرابات في التبول، جفاف الفم، ، فقدان الشعور بالألم، زيادة التعرق، إغماء، آلام مختلفة، إعياء وسقم، تضخم الثديين لدى الرجال، ضعف القدرة الجنسية، زيادة الوزن، نقص الوزن.</p><p dir="RTL"><strong><em>تأثيرات نادرة (يمكن ان تصيب لغاية&nbsp; 1 من بين كل 1000 شخص)</em></strong><strong><em>:</em></strong></p><p dir="RTL">ارتباك وتشوش.</p><p dir="RTL"><strong><em>تأثيرات نادرة جداً (يمكن ان تصيب لغاية&nbsp; 1 من بين كل 10000 شخص)</em></strong><strong><em>:</em></strong></p><p dir="RTL">ردود فعل حساسية، نتائج غير طبيعية لتحاليل وظائف الكبد، التهاب الكبد، اصفرار الجلد (يرقان)، انخفاض تعداد كريات الدم البيضاء والصفائح الدموية، ارتفاع مستوى الجلوكوز في الدم، نوبة قلبية (احتشاء بعضلة القلب)، ردود فعل حساسية شديدة بالجلد (طفح جلدي ظهور قشور او حدوث تقشر بالجلد)، ردود فعل حساسية شديدة مصحوبة بحمى وبقع حمراء على الجلد وآلام بالعضلات والمفاصل واضطرابات في العينين(متلازمة ستيفنز- جونسون)، تورم الشفتين والجفون والأعضاء التناسلية (وذمة كوينكي)، تورم او التهاب اللثة، التهاب البنكرياس، التهاب بطانة المعدة، حساسية للضوء، زيادة توتر العضلات، اعتلالات عصبية طرفية (خلل عصبي يسبب ضعف في الإحساس وتنميل)، التهاب الأوعية الدموية.</p><p dir="RTL"><strong><em>تأثيرات غير معروفة (لا يمكن تقدير معدلات الحدوث من واقع البيانات المتوفرة)</em></strong><strong><em>:</em></strong></p><p dir="RTL">ارتجاف، تصلب في وضعية الجسم، وجه شبيه بالقناع، بطء الحركة والتلكؤ، مشية غير متوازنة.</p><p dir="RTL"><strong><u>ليزينوبريل</u></strong>:</p><p dir="RTL"><strong><em>تأثيرات شائعة (يمكن ان تصيب لغاية&nbsp; 1 من بين كل 10 شخص)</em></strong><strong><em>:</em></strong></p><p dir="RTL">صداع، دوار او خواء خاصة عند النهوض والوقوف بسرعة، إسهال، سعال، تقيؤ، مشاكل في الكلى.</p><p dir="RTL"><strong><em>تأثيرات غير شائعة (يمكن ان تصيب لغاية&nbsp; 1 من بين كل 100 شخص) </em></strong><strong><em>:</em></strong></p><p dir="RTL">تغيرات في المزاج، تغير لون الجلد (ازرق باهت يليه احمرار)، و/أو خدر أو تنميل في اصابع اليدين أو أصابع القدمين (ظاهرة ريناود)تغيرات في طعم الأشياء، هلوسات (رؤية أو سماع اشياء غير حقيقية)، دوار، احساسات غير طبيعية بالجلد (مثل التنميل او الحكة أو الحرقان)، شعور بتسارع او عدم انتظام نبضات القلب (خفقان القلب)، نوبة قلبية (احتشاء بعضلة القلب)، جلطة دماغية، رشح من الأنف، غثيان (شعور بالسقم) ألم بالمعدة أو عسر الهضم، ضعف القدرة الجنسية، تعب، تغيرات في نتائج بعض التحاليل المخبرية (التي توضح كيفية عمل الكلى)، طفح جلدي، حكة،تسارع نبضات القلب.&nbsp; &nbsp;</p><p dir="RTL"><strong><em>تأثيرات نادرة (يمكن ان تصيب لغاية&nbsp; 1 من بين كل 1000 شخص)</em></strong><strong><em>:</em></strong></p><p dir="RTL">وذمة وعائية (وهي ردة فعلل حساسية شديدة تشمل أعراضها الحكة والطفح الجلدي وأزيز تنفسي وتورمات في الشفتين والوجه والعنق وأحيانا اليدين والقدمين، وتكون معدلات الإصابة بالوذمة الوعائية لدى العرق الأسود اعلى مما هي لدى العرق الأبيض)، ارتباك وتشوش، افرازات غير طبيعية للهرمون المضاد لإدرار البول الذي يتحكم في كمية البول التي يفرزها الجسم، مشاكل حادة في الكلى، فشل كلوي، جفاف الفم، تساقط الشعر، صدفية شرى (حكة مع حرقان بالجلد) تضخم الثديين لدى الرجال، تغيرات في روائح الأشياء.</p><p dir="RTL">تفاقم صورة تحاليل الدم: تشمل انخفاض مستوى الهيموجلوبين والراسب الدموي، ارتفاع مستوى البيليروبين (صبغة الصفراء) انخفاض مستوى الصوديوم في الدم.</p><p dir="RTL"><strong><em>تأثيرات نادرة جداً (يمكن ان تصيب لغاية&nbsp; 1 من بين كل 10000 شخص)</em></strong><strong><em>:</em></strong></p><p dir="RTL">انخفاض مستوى الجلوكوز في الدم، الم جيبي وأزيز في التنفس، التهاب رئوي، اصفرار الجلد و/أو العينين (يرقان)، التهاب الكبد والبنكرياس، فشل الكبد، اضطرابات شديدة بالجلد (تشمل الأعراض احمرار الجلد وظهور النفط والتقشر)، تعرق.</p><p dir="RTL">نقص في كمية البول التي يفرزها الجسم او حتى توقف إفراز البول، وذمة في الأمعاء،&nbsp;</p><p dir="RTL">تفاقم صورة تعداد الدم وتشمل أعراضها: انخفاض تعداد كريات الدم الحمراء (فقر الدم)،</p><p dir="RTL">تفاقم صورة تحاليل الدم وتشمل أعراضها: انخفاض تعداد الصفائح الدموية ، انخفاض تعداد الكريات البيضاء، وهذه المشاكل قد تسبب النزيف طويل الأمد والتعب والضعف ومرض الغدد اللمفاوية وخلل مناعي ذاتي (حيث ينتج جهاز المناعة اجساماً مضادة لأنسجة الجسم نفسها). ويمكن ان تصبح اكثر عرضة للإصابات والعدوى.</p><p dir="RTL"><strong><em>تأثيرات غير معروفة (لا يمكن تقدير معدلات الحدوث من واقع البيانات المتوفرة)</em></strong><strong><em>:</em></strong></p><p dir="RTL">إغماء، اكتئاب ، تفاعلات فرط الحساسية التحسسية الشديدة (تفاعلات تأقية / تأقانية).</p><p dir="RTL"><strong>الإبلاغ عن التأثيرات الجانبية</strong><strong>:</strong></p><p dir="RTL">إذا ظهرت لديك أي من التأثيرات الجانبية فيجب التحدث إلى الطبيب أو الصيدلي. وتشمل تلك الأعراض اي تأثيرات محتملة اخرى لم يرد ذكرها في هذه النشرة. ومن خلال إبلاغك عن تلك الآثار الجانبية فإنك تساعد في تقديم المزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">للإبلاغ عن أي عرض جانبي :</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المملكة العربية السعودية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المركز الوطني للتيقظ الدوائي :</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رقم هاتف المركز : 19999</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الالكتروني : npc.drug@sfda.gov.sa</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الالكتروني : https://ade.sfda.gov.sa/</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دول مجلس التعاون</p><p><!--[if gte vml 1]><v:rect
 id="Rectangle_x0020_2" o:spid="_x0000_s1026" style='position:absolute;left:0;
 text-align:left;margin-left:0;margin-top:6.35pt;width:512.45pt;height:42.35pt;
 z-index:251660288;visibility:visible;mso-wrap-style:square;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:left;mso-position-horizontal-relative:margin;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-height-percent:0;mso-height-relative:margin;v-text-anchor:middle'
 o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" strokecolor="black [3213]" strokeweight="1pt">
 <w:wrap anchorx="margin"/>
</v:rect><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p>يرجى الاتصال بالسلطة المختصة ذات الصلة</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">- &nbsp;يحفظ هذا الدواء بعيدًا عن مرأى ومتناول أيدي الأطفال.</p><p dir="RTL">- لا تستخدم هذا المستحضر بعد تاريخ انتهاء الصلاحية المدون على العبوة الخارجية والملصق بعد الرمز &quot;EXP&quot; الذي يشير تاريخ انتهاء الصلاحية إلى آخر يوم في ذلك الشهر.</p><p dir="RTL">- يحفظ في درجة حرارة لا تزيد عن 30 درجة مئوية.</p><p dir="RTL">- لا تستخدم هذا المستحضر إذا لاحظت أن العبوة تالفة أو تظهر عليها علامات العبث.</p><p dir="RTL">&nbsp;-لا تتخلص من الأدوية في مياه الصرف الصحي أو النفايات المنزلية.</p><p dir="RTL">اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. تساعد هذه التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المواد الفعالة هي &quot;ليزينوبريل&quot; و&quot;أملودبين&quot;</p><p dir="RTL"><u>ليزونورم 10ملجم/5ملجم:</u></p><p dir="RTL">كل قرص يحتوي على 10ملجم ليزينوبريل (على هيئة دايهايدريت) و5 ملجم أملودبين (على هيئة بيسايليت)</p><p dir="RTL"><u>ليزونورم 20ملجم/10ملجم:</u></p><p dir="RTL">كل قرص يحتوي على 20ملجم ليزينوبريل (على هيئة دايهايدريت) و10 ملجم أملودبين (على هيئة بيسايليت)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; المكونات الأخرى هي:</p><p dir="RTL">سليولوز مبلور دقيق، نشا جليكولات صوديوم، (نوع-أ)، ستيارات المغنيسيوم</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><u>ليزونورم 10ملجم/5ملجم:</u></p><p dir="RTL">أقراص دائرية مسطحة بلون ابيض او تقريبا ابيض يتوسطها خط تقسيم غائر على احد الوجهين وعلى الوجه الآخر محفور &quot;A+L&quot; بخط غائر. ويبلغ قطر القرص حوالي 8 ملم.</p><p dir="RTL">تحتوي العبوة على 30 قرصاً في شرائح بثورية من مواد &quot;بي في سي/بي إي/بي في دي سي- الومنيوم&quot; &nbsp;معبأة في علبة من الورق المقوى (الكرتون).</p><p dir="RTL"><u>ليزونورم 20ملجم/10ملجم:</u></p><p dir="RTL">أقراص دائرية محدبة الوجهين بلون ابيض او تقريبا ابيض محفور على احد الوجهين &quot;CF3&quot; بخط غائر. ولا توجد علامات على الوجه الآخر. ويبلغ قطر القرص حوالي 11ملم.</p><p dir="RTL">تحتوي العبوة على 30 قرصاً في شرائح من مواد &quot;بي في سي/بي إي/بي في دي سي- الومنيوم&quot;&nbsp; معبأة في علبة من الورق المقوى (الكرتون).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>حامل ترخيص التسويق </strong></p><p dir="RTL">شركة أجا للصناعات الدوائية المحدودة</p><p dir="RTL">المدينة الصناعية مدن بحائل ، شارع رقم 32</p><p dir="RTL">ص.ب. 6979، حائل 55414</p><p dir="RTL">المملكة العربية السعودية</p><p dir="RTL">تمت مراجعة على هذة النشرة في يوليو 2023</p><p><strong>الشركة المصنعة</strong></p><p>شركة جوديون ريختر</p><p>بودابست &ndash; المجر</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ 07/2023م
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lisonorm 10 mg/5 mg tablets
Lisonorm 20 mg/10 mg tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lisonorm10mg/5 mg tablets:
Each tablet contains 10 mg lisinopril (as dihydrate) and 5 mg amlodipine (as besilate).

Lisonorm20 mg/10 mg tablets:
Each tablet contains 20 mg lisinopril (as dihydrate) and 10 mg amlodipine (as besilate). 
Excipient with known effect: sodium
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablet.

Lisonorm10 mg/5 mg tablets:
White or almost white, round, flat, bevel-edged tablet with a score line on one side and with an engraving “A+L” on the other side. Diameter: approx. 8 mm
The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses.

Lisonorm20 mg/10 mg tablets:
White or almost white, round, biconvex tablet with engraving on one side: “CF3”, other side without engraving. Diameter approx. 11 mm.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of essential hypertension in adults.</p><p>&nbsp;</p><p>Lisonorm is indicated as substitution therapy of adult patients with blood pressure adequately controlled with lisinopril and amlodipine given concurrently at the same dose level.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>&nbsp;</p><p>The recommended dose is one tablet daily. The maximum daily dose is one tablet. In general, fixed dose combination preparations are not suitable for initial therapy.</p><p>Lisonorm is indicated only for patients in whom the optimal maintenance dose of lisinopril and amlodipine has been titrated to 10 mg and 5 mg in case of Lisonorm10 mg/5 mg, 20 mg and 10 mg in case of Lisonorm20 mg/10 mg and 20 mg and 5 mg in case of Lisonorm20 mg/5 mg tablets respectively.</p><p>If dose adjustment becomes necessary, dose titration with the individual components can be considered.</p><p>&nbsp;</p><p><em>Renal</em><em> </em><em>impairment</em></p><p>To find the optimal starting dose and maintenance dose of patients with renal impairment, the patients should be individually titrated using the individual components of lisinopril and amlodipine.</p><p>Renal function, serum potassium and sodium levels should be monitored during therapy with Lisonorm. In the case of renal function deterioration, the use of Lisonorm should be discontinued and replaced by the individual components adequately adjusted. Amlodipine is not dialyzable.</p><p>&nbsp;</p><p><em>Hepatic</em><em> impairment</em></p><p>Dosage recommendations have not been established in patients with mild to moderate hepatic impairment; therefore dose selection should be cautious and should start at the lower end of the dosing range (see sections 4.4 and 5.2). To find the optimal starting dose and maintenance dose of patients with hepatic impairment, the patients should be individually titrated using the free combination of lisinopril and amlodipine.</p><p>The pharmacokinetics of amlodipine have not been studied in severe hepatic impairment. Amlodipine should be initiated at the lowest dose and titrated slowly in patients with severe hepatic impairment.</p><p>&nbsp;</p><p><em>Paediatric</em><em> population (&lt;18 years)</em></p><p>The safety and efficacy of Lisonorm in children and adolescents aged below 18 years have not been established.</p><p>&nbsp;</p><p><em>Elderly</em><em> </em><em>(&gt;65</em><em> </em><em>years)</em></p><p>Elderly patients should be treated with caution.</p><p>In clinical studies, there was no age-related change in the efficacy or safety profile of amlodipine or lisinopril. To find the optimal maintenance dose of elderly patients they should be individually titrated using the free combination of lisinopril and amlodipine.</p><p>&nbsp;</p><p><u>Method</u><u> of administration</u> For oral administration</p><p>&nbsp;</p><p>Since food does not affect absorption, Lisonorm may be taken irrespective of meals, i.e. before, during or after meals.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Related to lisinopril:
-	Hypersensitivity to lisinopril or to any other angiotensin converting enzyme (ACE) inhibitor
-	A history of angioedema associated with previous ACE inhibitor therapy
-	Hereditary or idiopathic angioedema.
-	2nd and 3rd trimester of pregnancy (see sections4.4 and 4.6)
-	The concomitant use of Lisonorm with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 mL/min/1.73 m2) (see sections 4.5 and 5.1).
-	The concomitant use with sacubitril/valsartan therapy. Lisonorm must not be initiated earlier than 36 hours after the last dose of sacubitril/valsartan (see also sections 4.4 and 4.5).

Related to amlodipine:
-	Hypersensitivity to amlodipine or to any other dihydropyridine derivatives
-	Severe hypotension
-	Shock (including cardiogenic shock)
-	Obstruction in the outflow tract of the left ventricle (high grade aortic stenosis)
-	Haemodynamically unstable heart failure after acute myocardial infarction

Related to Lisonorm:
All of the above detailed contraindications related to the individual monocomponents are also relating to the fixed combination Lisonorm.
-	Hypersensitivity to any of the excipients listed in section6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>All of the warnings with regard to the individual monocomponents detailed below are also relating to the fixed combination Lisonorm.</p><p>&nbsp;</p><p><em>Related</em><em> </em><em>to lisinopril:</em></p><p><em><u>Symptomatic</u></em><em><u> </u></em><em><u>hypotension</u></em></p><p>Symptomatic hypotension is seen rarely in uncomplicated hypertensive patients. In hypertensive patients receiving lisinopril, hypotension is more likely to occur if the patient has been volume&ndash; depleted e.g. by diuretic therapy, dietary salt restriction, dialysis, diarrhoea or vomiting, or has severe renin-dependent hypertension (see section 4.5 and section 4.8). In patients with heart failure with or without associated renal insufficiency, symptomatic hypotension has been observed. This is most likely to occur in those patients with more severe degrees of heart failure, as reflected by the use of high doses of loop diuretics, hyponatraemia or functional renal impairment. In patients at increased risk of symptomatic hypotension, initiation of therapy and dose adjustment should be closely monitored. Similar considerations apply to patients with ischaemic heart or cerebrovascular disease in whom an excessive fall in blood pressure could result in a myocardial infarction or cerebrovascular accident.</p><p>&nbsp;</p><p>If hypotension occurs, the patient should be placed in the supine position and, if necessary, should receive an intravenous infusion of normal saline. A transient hypotensive response is not a contraindication to further doses, which can be given usually without difficulty once the blood pressure has increased after volume expansion.</p><p>In some patients with heart failure who have normal or low blood pressure, additional lowering of systemic blood pressure may occur with lisinopril. This effect is anticipated and is not usually a reason to discontinue treatment. If hypotension becomes symptomatic, a reduction of dose or discontinuation of lisinopril may be necessary.</p><p>&nbsp;</p><p><em><u>Hypotension</u></em><em><u> in acute myocardial infarction</u></em></p><p>Treatment with lisinopril must not be initiated in <u>acute myocardial infarction patients </u>who are at risk of further serious haemodynamic deterioration after treatment with a vasodilator. These are patients with systolic blood pressure of 100 mmHg or lower or those in cardiogenic shock. During the first 3 days following the infarction, the dose should be reduced if the systolic blood pressure is 120 mmHg or lower. Maintenance doses should be reduced to 5 mg or temporarily 2.5 mg if systolic blood pressure is 100 mmHg or lower. If hypotension persists (systolic blood pressure less than 90 mmHg for more than 1 hour), then lisinopril should be withdrawn.</p><p>&nbsp;</p><p><em><u>Aortic</u></em><em><u> and mitral valve stenosis/hypertrophic cardiomyopathy</u></em></p><p>As with other ACE inhibitors, lisinopril should be given with caution to patients with mitral valve stenosis and obstruction in the outflow of the left ventricle such as aortic stenosis or hypertrophic cardiomyopathy.</p><p>&nbsp;</p><p><em><u>Renal</u></em><em><u> </u></em><em><u>impairment</u></em></p><p>In cases of renal impairment (creatinine clearance &lt;80 mL/min), the initial lisinopril dosage should be adjusted according to the patient&#39;s creatinine clearance, and then as a function of the patient&#39;s response to treatment. Routine monitoring of potassium and creatinine is part of normal medical practice for these patients.</p><p>In patients with <u>heart failure</u>, hypotension following the initiation of therapy with ACE inhibitors may lead to some further impairment in renal function. Acute renal failure, usually reversible, has been reported in this situation.</p><p>In some patients with bilateral renal artery stenosis or with a stenosis of the artery to a solitary kidney, who have been treated with angiotensin converting enzyme inhibitors, increases in blood urea and serum creatinine, usually reversible upon discontinuation of therapy, have been seen. This is especially likely in patients with renal insufficiency. If renovascular hypertension is also present there is an increased risk of severe hypotension and renal insufficiency. In these patients, treatment should be started under close medical supervision with low doses and careful dose titration. Since treatment with diuretics may be a contributory factor to the above, they should be discontinued and renal function should be monitored during the first weeks of lisinopril therapy.</p><p>Some <u>hypertensive patients </u>with no apparent pre-existing renal vascular disease have developed increases in blood urea and serum creatinine, usually minor and transient, especially when lisinopril has been given concomitantly with a diuretic. This is more likely to occur in patients with pre-existing renal impairment. Dosage reduction and/or discontinuation of the diuretic and/or lisinopril may be required.</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape id="_x0000_s2050"
 style='position:absolute;left:0;text-align:left;margin-left:415.85pt;
 margin-top:14.6pt;width:2.9pt;height:1pt;z-index:-251660800;
 mso-position-horizontal-relative:page;mso-position-vertical-relative:text'
 coordsize="58,20" o:allowincell="f" path="m,hhl58,e" filled="f"
 strokeweight=".48pt">
 <v:path arrowok="t"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="6" height="2" src="file:///C:/Users/101166/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png" />In <u>acute myocardial infarction</u>, treatment with lisinopril should not be initiated in patients with evidence of renal dysfunction, defined as serum creatinine concentration exceeding 177 micromol/l and/or proteinuria exceeding 500 mg/24 hour. If renal dysfunction develops during treatment with lisinopril (serum creatinine concentration exceeding 265 micromol/l or a doubling from the pre- treatment value) then the physician should consider withdrawal of lisinopril.</p><p>&nbsp;</p><p><em><u>Hypersensitivity,</u></em><em><u> </u></em><em><u>angioedema</u></em></p><p>Angioedema of the face, extremities, lips, tongue, glottis and/or larynx has been reported rarely in patients treated with angiotensin-converting enzyme inhibitors, including lisinopril. This may occur at any time during therapy. In such cases, lisinopril should be discontinued promptly and appropriate treatment and monitoring should be instituted to ensure complete resolution of symptoms prior to dismissing the patients. Even in those instances where swelling of only the tongue is involved, without respiratory distress, patients may require prolonged observation since treatment with antihistamines and corticosteroids may not be sufficient.</p><p>Very rarely, fatalities have been reported due to angioedema associated with laryngeal oedema or tongue oedema. Patients with involvement of the tongue, glottis or larynx are likely to experience airway obstruction, especially those with a history of airway surgery. In such cases emergency therapy should be administered promptly. This may include the administration of adrenaline and/or the maintenance of a patent airway. The patient should be under close medical supervision until complete and sustained resolution of symptoms has occurred.</p><p>Angiotensin converting enzyme inhibitors cause a higher rate of angioedema in black patients than in non-black patients.</p><p>Patients with a history of angioedema unrelated to ACE inhibitor therapy may be at increased risk of angioedema while receiving an ACE inhibitor (see section 4.3).</p><p>Concomitant use of ACE inhibitors with sacubitril/valsartan is contraindicated due to the increased risk of angioedema. Treatment with sacubitril/valsartan must not be initiated earlier than 36&nbsp;hours after the last dose of lisinopril. Treatment with lisinopril must not be initiated earlier than 36&nbsp;hours after the last dose of sacubitril/valsartan (see sections 4.3 and 4.5).</p><p>Concomitant use of ACE inhibitors with racecadotril, mTOR inhibitors (e.g. sirolimus, everolimus, temsirolimus) and vildagliptin may lead to an increased risk of angioedema (e.g. swelling of the airways or tongue, with or without respiratory impairment) (see section 4.5). Caution should be used when starting racecadotril, mTOR inhibitors and vildagliptin in a patient already taking an ACE inhibitor.</p><p>&nbsp;</p><p><em><u>Anaphylactoid</u></em><em><u> </u></em><em><u>reactions</u></em><em><u> </u></em><em><u>in haemodialysis patients</u></em></p><p>Anaphylactoid reactions have been reported in patients dialysed with high-flux membranes (e.g. AN69) and treated concomitantly with an ACE inhibitor. In these patients consideration should be given to using a different type of dialysis membrane or different class of antihypertensive agent.</p><p>&nbsp;</p><p><em><u>Anaphylactoid</u></em><em><u> </u></em><em><u>reactions</u></em><em><u> </u></em><em><u>during</u></em><em><u> </u></em><em><u>low-density</u></em><em><u> lipoproteins (LDL) apheresis</u></em></p><p>Rarely, patients receiving ACE inhibitors during low-density lipoproteins (LDL) apheresis with dextran sulphate have experienced life-threatening anaphylactoid reactions. These reactions were avoided by temporarily withholding ACE inhibitor therapy prior to each apheresis.</p><p>&nbsp;</p><p><em><u>Desensitization</u></em></p><p>Patients receiving ACE inhibitors during desensitisation treatment (e.g. Hymenoptera venom) have sustained anaphylactoid reactions. In the same patients, these reactions have been avoided when ACE inhibitors were temporarily withheld but they have reappeared upon inadvertent re-administration of the medicinal product.</p><p>&nbsp;</p><p><em><u>Hepatic</u></em><em><u> failure</u></em></p><p>Very rarely, ACE inhibitors have been associated with a syndrome that starts with cholestatic jaundice and progresses to fulminant necrosis and (sometimes) death. The mechanism of this syndrome is not understood. Patients receiving lisinopril who develop jaundice or marked elevations of hepatic enzymes should discontinue lisinopril and receive appropriate medical follow-up.</p><p>&nbsp;</p><p><em><u>Neutropenia/agranulocytosis</u></em></p><p>Neutropenia/agranulocytosis, thrombocytopenia and anaemia have been reported in patients receiving ACE inhibitors. In patients with normal renal function and no other complicating factors, neutropenia occurs rarely. Neutropenia and agranulocytosis are reversible after discontinuation of the ACE inhibitor.</p><p>Lisinopril should be used with extreme caution in patients with collagen vascular disease, immunosuppressant therapy, treatment with allopurinol or procainamide, or a combination of these complicating factors, especially if there is pre-existing impaired renal function. Some of these patients developed serious infections, which in a few instances did not respond to intensive antibiotic therapy. If lisinopril is used in such patients, periodic monitoring of white blood cell counts is advised and patients should be instructed to report any sign of infection.</p><p>&nbsp;</p><p><em><u>Dual</u></em><em><u> </u></em><em><u>blockade</u></em><em><u> of the renin-angiotensin-aldosterone system (RAAS)</u></em></p><p>There is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren increases the risk of hypotension, hyperkalaemia and decreased renal function (including acute renal failure). Dual blockade of RAAS through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is therefore not recommended (see sections 4.5 and 5.1).</p><p>If dual blockade therapy is considered absolutely necessary, this should only occur under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure. ACE-inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients with diabetic nephropathy.</p><p>&nbsp;</p><p><em><u>Race</u></em></p><p>Angiotensin converting enzyme inhibitors cause a higher rate of angioedema in black patients than in non-black patients.</p><p>As with other ACE inhibitors, lisinopril may be less effective in lowering blood pressure in black patients than in non-blacks, possibly because of a higher prevalence of low-renin states in the black hypertensive population.</p><p>&nbsp;</p><p><em><u>Cough</u></em></p><p>Cough has been reported with the use of ACE inhibitors. Characteristically, the cough is non- productive, persistent and resolves after discontinuation of therapy. ACE inhibitor-induced cough should be considered as part of the differential diagnosis of cough.</p><p>&nbsp;</p><p><em><u>Surgery/anaesthesia</u></em></p><p>In patients undergoing major surgery or during anaesthesia with agents that produce hypotension, lisinopril may block angiotensin II formation secondary to compensatory renin release. If hypotension occurs and is considered to be due to this mechanism, it can be corrected by volume expansion.</p><p>&nbsp;</p><p><em><u>Hyperkalaemia</u></em></p><p>ACE inhibitors can cause hyperkalaemia because they inhibit the release of aldosterone. The effect is usually not significant in patients with normal renal function. However, in patients with impaired renal function, diabetes mellitus, and/or in patients taking potassium supplements (including salt substitutes), potassium-sparing diuretics (e.g. spironolactone, triamterene or amiloride), or those patients taking other medicines associated with increases in serum potassium (e.g. heparin, trimethoprim or the combination co-trimoxazole also known as trimethoprim/sulfamethoxazole) and especially aldosterone antagonists or angiotensin-receptor blockers, hyperkalaemia can occur. Potassium-sparing diuretics and angiotensin-receptor blockers should be used with caution in patients receiving ACE inhibitors. If concomitant use of the above-mentioned agents is deemed appropriate, serum potassium and renal function should be monitored (see section 4.5).</p><p>&nbsp;</p><p><em><u>Diabetic</u></em><em><u> </u></em><em><u>patients</u></em></p><p>In diabetic patients treated with oral antidiabetic agents or insulin, glycaemic control should be closely monitored during the first month of treatment with an ACE inhibitor (see section 4.5).</p><p>&nbsp;</p><p><em><u>Lithium</u></em></p><p>The combination of lithium and lisinopril is generally not recommended (see section 4.5).</p><p>&nbsp;</p><p><em><u>Pregnancy</u></em></p><p>ACE inhibitors should not be initiated during pregnancy. Unless continued ACE inhibitor therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with ACE inhibitors should be stopped immediately, and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6).</p><p>&nbsp;</p><p><em>Related</em><em> </em><em>to amlodipine</em></p><p><em>&nbsp;</em></p><p>The safety and efficacy of amlodipine in hypertensive crisis have not been established.</p><p>&nbsp;</p><p><em><u>Cardiac</u></em><em><u> failure</u></em></p><p>Patients with heart failure should be treated with caution. In a long-term, placebo controlled study in patients with severe heart failure (NYHA class III and IV) the reported incidence of pulmonary oedema was higher in the amlodipine treated group than in the placebo group (see section 5.1). Calcium channel blockers, including amlodipine, should be used with caution in patients with congestive heart failure, as they may increase the risk of future cardiovascular events and mortality.</p><p>&nbsp;</p><p><em><u>Hepatic</u></em><em><u> impairment</u></em></p><p>The half-life of amlodipine is prolonged and AUC values are higher in patients with impaired liver function, dosage recommendations have not been established. Amlodipine should therefore be initiated at the lower end of the dosing range and caution should be used, both on initial treatment and when increasing the dose. Slow dose titration and careful monitoring may be required in patients with severe hepatic impairment.</p><p>&nbsp;</p><p><em><u>Elderly</u></em></p><p>In the elderly increase of the dosage should take place with care (see sections 4.2 and 5.2).</p><p>&nbsp;</p><p><em><u>Renal</u></em><em><u> </u></em><em><u>impairment</u></em></p><p>Amlodipine may be used in such patients at normal doses. Changes in amlodipine plasma concentrations are not correlated with the degree of renal impairment. Amlodipine is not dialyzable.</p><p>&nbsp;</p><p><u>Related to Lisonorm:</u></p><p>This medicinal product contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per tablet, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Interactions</u><u> </u><u>related</u><u> </u><u>to lisinopril</u></p><p>&nbsp;</p><p><em>Antihypertensive</em><em> agents</em></p><p>When lisinopril is combined with other antihypertensive agents (e.g. glyceryl trinitrate and other nitrates, or other vasodilators), additive falls in blood pressure may occur.</p><p>Clinical trial data has shown that dual blockade of the renin-angiotensin-aldosterone-system (RAAS) through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure) compared to the use of a single RAAS acting agent (see sections 4.3, 4.4 and 5.1).</p><p>&nbsp;</p><p><em>Medicines that may increase the risk of angioedema</em></p><p>Concomitant use of ACE inhibitors with sacubitril/valsartan is contraindicated as this increases the risk of angioedema (see section 4.3 and 4.4).</p><p>Concomitant use of ACE inhibitors with mammalian target of rapamycin (mTOR) inhibitors (e.g. temsirolimus, sirolimus, everolimus) or neutral endopeptidase (NEP) inhibitors (e.g. racecadotril) or tissue plasminogen activator or vildagliptin may lead to an increased risk for angioedema (see section 4.4).</p><p>&nbsp;</p><p><em>Diuretics</em></p><p>When a diuretic is added to the therapy of a patient receiving lisinopril the antihypertensive effect is usually additive. Patients already on diuretics and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure when lisinopril is added. The possibility of symptomatic hypotension with lisinopril can be minimised by discontinuing the diuretic prior to initiation of treatment with lisinopril (see section 4.4 and section 4.2).</p><p>&nbsp;</p><p><em>Potassium supplements,</em><em> potassium-sparing diuretics or potassium-containing salt substitutes and other medicines that may increase serum potassium levels</em></p><p>Although in clinical trials, serum potassium usually remains within normal limits, hyperkalaemia may occur in some patients. - treated with lisinopril. Potassium sparing diuretics (e.g. spironolactone, triamterene or amiloride), potassium supplements or potassium-containing salt substitutes may lead to significant increases in serum potassium, particularly in patients with impaired renal function. . Care should also be taken when lisinopril is co-administered with other agents that increase serum potassium, such as trimethoprim and co-trimoxazole (trimethoprim/sulfamethoxazole) as trimethoprim is known to act as a potassium-sparing diuretic like amiloride. Therefore, the combination of lisinopril with the above-mentioned medicines is not recommended. If concomitant use is indicated, they should be used with caution and with frequent monitoring of serum potassium. If lisinopril is given with a potassium-losing diuretic, diuretic-induced hypokalaemia may be ameliorated (see section 4.4).</p><p>&nbsp;</p><p><em>Ciclosporin</em></p><p>Hyperkalaemia may occur during concomitant use of ACE inhibitors with ciclosporin. Monitoring of serum potassium is recommended.</p><p>&nbsp;</p><p><em>Heparin</em></p><p>Hyperkalaemia may occur during concomitant use of ACE inhibitors with heparin. Monitoring of serum potassium is recommended.</p><p>&nbsp;</p><p><em>Lithium</em></p><p>Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors. Concomitant use of thiazide diuretics may increase the risk of lithium toxicity and enhance the already increased lithium toxicity with ACE inhibitors. Use of lisinopril with lithium is not recommended, but if the combination proves necessary, careful monitoring of serum lithium levels should be performed (see section 4.4).</p><p>&nbsp;</p><p><em>Non-steroidal</em><em> </em><em>anti-inflammatory</em><em> </em><em>drugs</em><em> </em><em>(NSAIDs)</em><em> </em><em>including</em><em> acetylsalicylic acid &ge;3 g/day </em>When ACE-inhibitors are administered simultaneously with non-steroidal anti-inflammatory drugs (i.e. acetylsalicylic acid at anti-inflammatory dosage regimens, COX-2 inhibitors and non-selective NSAIDs), attenuation of the antihypertensive effect may occur. Concomitant use of ACE-inhibitors and NSAIDs may lead to an increased risk of worsening of renal function, including possible acute renal failure, and an increase in serum potassium, especially in patients with poor pre-existing renal function. These effects are usually reversible. The combination should be administered with caution, especially in the elderly. Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy, and periodically thereafter.</p><p>&nbsp;</p><p><em>Gold</em></p><p>Nitritoid reactions (symptoms of vasodilatation including flushing, nausea, dizziness and hypotension, which can be very severe) following injectable gold (for example sodium aurothiomalate) have been reported more frequently in patients receiving ACE inhibitor therapy.</p><p>&nbsp;</p><p><em>Tricyclic</em><em> antidepressants/antipsychotics/anaesthetics</em></p><p>Concomitant use of certain anaesthetic medicinal products, tricyclic antidepressants and antipsychotics with ACE inhibitors may result in further reduction of blood pressure (see section 4.4).</p><p>&nbsp;</p><p><em>Sympathomimetics</em></p><p>Sympathomimetics may reduce the antihypertensive effect of ACE inhibitors.</p><p>&nbsp;</p><p><em>Antidiabetics</em></p><p>Epidemiological studies have suggested that concomitant administration of ACE inhibitors and antidiabetic medicines (insulins, oral hypoglycaemic agents) may cause an increased blood glucose lowering effect with risk of hypoglycaemia. This phenomenon appeared to be more likely to occur during the first weeks of combined treatment and in patients with renal impairment.</p><p>&nbsp;</p><p><em>Acetylsalicylic</em><em> acid, thrombolytics, beta-blockers, nitrates</em></p><p>Lisinopril may be used concomitantly with acetylsalicylic acid (at cardiologic doses), thrombolytics, beta-blockers and/or nitrates.</p><p>&nbsp;</p><p><u>Interactions</u><u> </u><u>related</u><u> </u><u>to amlodipine</u></p><p>&nbsp;</p><p><em><u>Effects</u></em><em><u> of other medicinal products on amlodipine</u></em></p><p><em>&nbsp;</em></p><p><em>CYP3A4</em><em> inhibitors</em></p><p>Concomitant use of amlodipine with strong or moderate CYP3A4 inhibitors (protease inhibitors, azole antifungals, macrolides like erythromycin or clarithromycin, verapamil or diltiazem) may give rise to significant increase in amlodipine exposure resulting in an increased risk of hypotension. The clinical translation of these PK variations may be more pronounced in the elderly. Clinical monitoring is recommended and dose adjustment may thus be required.</p><p>Clarithromycin is an inhibitor of CYP3A4. There is an increased risk of hypotension in patients receiving clarithromycin with amlodipine. Close observation of patients is recommended when amlodipine is co administered with clarithromycin.</p><p>&nbsp;</p><p><em>CYP3A4</em><em> inducers</em></p><p>Upon co-administration of known inducers of the CYP3A4, the plasma concentration of amlodipine may vary. Therefore, blood pressure should be monitored and dose regulation considered both during and after concomitant &nbsp;medication particularly with strong CYP3A4 inducers (e.g., rifampicin, St. John&#39;s wort [Hypericum perforatum]).</p><p>&nbsp;</p><p>Administration of amlodipine with grapefruit or grapefruit juice is not recommended as bioavailability may be increased in some patients resulting in increased blood pressure lowering effects.</p><p>&nbsp;</p><p><em>Dantrolene</em><em> </em><em>(infusion)</em></p><p>In animals, lethal ventricular fibrillation and cardiovascular collapse are observed in association with hyperkalaemia after administration of verapamil and intravenous dantrolene. Due to risk of hyperkalaemia, it is recommended that the co-administration of calcium channel blockers such as amlodipine be avoided in patients susceptible to malignant hyperthermia and in the management of malignant hyperthermia.</p><p>&nbsp;</p><p><em><u>Effects</u></em><em><u> of amlodipine on other medicinal products</u></em></p><p><em>&nbsp;</em></p><p>The blood pressure lowering effects of amlodipine adds to the blood pressure-lowering effects of other medicinal products with antihypertensive properties.</p><p>&nbsp;</p><p><em>Tacrolimus</em></p><p>There is a risk of increased tacrolimus blood levels when co-administered with amlodipine but the pharmacokinetic mechanism of this interaction is not fully understood. In order to avoid toxicity of tacrolimus, administration of amlodipine in a patient treated with tacrolimus requires monitoring of tacrolimus blood levels and dose adjustment of tacrolimus when appropriate.</p><p>&nbsp;</p><p><em>Mammalian Target of Rapamycin (mTOR) Inhibitors</em></p><p>mTOR inhibitors such as sirolimus, temsirolimus, and everolimus are CYP3A substrates. Amlodipine is a weak CYP3A inhibitor. With concomitant use of mTOR inhibitors, amlodipine may increase exposure of mTOR inhibitors.</p><p>&nbsp;</p><p><em>Ciclosporin</em></p><p>No drug interaction studies have been conducted with ciclosporin and amlodipine in healthy volunteers or other populations with the exception of renal transplant patients, where variable trough concentration increases (average 0% - 40%) of ciclosporin were observed. Consideration should be given for monitoring ciclosporin levels in renal transplant patients on amlodipine, and ciclosporin dose reductions should be made as necessary.</p><p>&nbsp;</p><p><em>Simvastatin</em></p><p>Co-administration of multiple doses of 10 mg of amlodipine with 80 mg simvastatin resulted in a 77% increase in exposure to simvastatin compared to simvastatin alone. Limit the dose of simvastatin in patients on amlodipine to 20 mg daily.</p><p>&nbsp;</p><p>In clinical interaction studies, amlodipine did not affect the pharmacokinetics of atorvastatin, digoxin or warfarin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>&nbsp;</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
lang=EN-GB style='font-size:10.0pt;mso-ansi-language:EN-GB'><span
style='mso-element:field-begin;mso-field-lock:yes'></span>SHAPE<span
style='mso-spacerun:yes'>  </span>\* MERGEFORMAT<span style='mso-element:field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="_x0000_s1031" type="#_x0000_t202" style='width:464.65pt;
 height:26.65pt;mso-position-horizontal-relative:char;
 mso-position-vertical-relative:line' o:allowincell="f" filled="f"
 strokeweight=".48pt">
 <v:textbox style='mso-next-textbox:#_x0000_s1031' inset="0,0,0,0">
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoBodyText style='margin-top:.1pt;margin-right:75.65pt;
    margin-bottom:0in;margin-left:5.25pt;margin-bottom:.0001pt;line-height:
    101%;punctuation-wrap:simple;mso-line-break-override:restrictions'><span
    lang=EN-GB style='letter-spacing:-.05pt;mso-ansi-language:EN-GB'>The</span><span
    lang=EN-GB style='mso-ansi-language:EN-GB'> use<span style='letter-spacing:
    -.1pt'> </span>of<span style='letter-spacing:.05pt'> </span><span
    style='letter-spacing:-.05pt'>Lisonorm</span><span style='letter-spacing:
    .05pt'> </span><span style='letter-spacing:-.05pt'>is</span> <span
    style='letter-spacing:-.05pt'>not</span><span style='letter-spacing:-.1pt'>
    </span><span style='letter-spacing:-.05pt'>recommended</span> <span
    style='letter-spacing:-.05pt'>during</span><span style='letter-spacing:
    -.15pt'> </span><span style='letter-spacing:-.05pt'>the</span> <span
    style='letter-spacing:-.05pt'>first</span><span style='letter-spacing:-.1pt'>
    </span><span style='letter-spacing:-.05pt'>trimester</span><span
    style='letter-spacing:.05pt'> </span>of<span style='letter-spacing:-.1pt'> </span><span
    style='letter-spacing:-.05pt'>pregnancy</span> <span style='letter-spacing:
    -.05pt'>and</span> is<span style='letter-spacing:2.05pt'> </span><span
    style='letter-spacing:-.05pt'>contraindicated</span> <span
    style='letter-spacing:-.05pt'>during</span> <span style='letter-spacing:
    -.05pt'>the</span> <span style='letter-spacing:-.05pt'>second</span><span
    style='letter-spacing:-.15pt'> </span>and <span style='letter-spacing:-.05pt'>third</span>
    <span style='letter-spacing:-.05pt'>trimesters</span><span
    style='letter-spacing:-.1pt'> of</span><span style='letter-spacing:.05pt'> </span><span
    style='letter-spacing:-.05pt'>pregnancy.<o:p></o:p></span></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
</v:shape><![endif]--><img width="626" height="41" alt="Text Box: The use of Lisonorm is not recommended during the first trimester of pregnancy and is contraindicated during the second and third trimesters of pregnancy." src="file:///C:/Users/101166/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png" /><!--[if gte vml 1]><v:shapetype id="_x0000_t75"
 coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
 filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><span
lang=EN-GB style='font-size:10.0pt;mso-ansi-language:EN-GB'><v:shape id="_x0000_i1025"
 type="#_x0000_t75" style='width:464.65pt;height:26.65pt'>
 <v:imagedata croptop="-1" cropbottom="1"/>
 <o:lock v:ext="edit" rotation="t" position="t"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p>No experience is available with the use of lisinopril and amlodipine in pregnant women from adequately controlled clinical studies. However, the use of both active substances during pregnancy is either not recommended or contraindicated (for substance-specific details, see below).</p><p>&nbsp;</p><p>When pregnancy is diagnosed, treatment with Lisonorm should be stopped immediately and, if appropriate, alternative therapy should be started (see section 4.4).</p><p>Lisonorm should not be initiated during pregnancy. Unless continued Lisonorm therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments with an established safety profile for use in pregnancy.</p><p>&nbsp;</p><p><em>Linked to lisinopril</em></p><p><em>&nbsp;</em></p><p><!--[if mso & !supportInlineShapes & supportFields]><span
lang=EN-GB style='font-size:10.0pt;mso-ansi-language:EN-GB'><span
style='mso-element:field-begin;mso-field-lock:yes'></span>SHAPE<span
style='mso-spacerun:yes'>  </span>\* MERGEFORMAT<span style='mso-element:field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:group
 id="_x0000_s1026" style='width:465.1pt;height:39.85pt;
 mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
 coordsize="9302,797" o:allowincell="f">
 <v:shape id="_x0000_s1027" style='position:absolute;left:8;top:9;width:9284;
  height:20;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:page' coordsize="9284,20" o:allowincell="f"
  path="m,hhl9284,e" filled="f" strokeweight=".48pt">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1028" style='position:absolute;left:4;top:4;
  width:20;height:787;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:page' coordsize="20,787" o:allowincell="f"
  path="m,hhl,786e" filled="f" strokeweight=".48pt">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1029" style='position:absolute;left:9296;top:4;
  width:20;height:787;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:page' coordsize="20,787" o:allowincell="f"
  path="m,hhl,786e" filled="f" strokeweight=".48pt">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1030" type="#_x0000_t202" style='position:absolute;
  left:5;top:10;width:9292;height:782;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:page' o:allowincell="f" filled="f"
  strokecolor="black [3213]">
  <v:textbox style='mso-next-textbox:#_x0000_s1030' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText style='margin-top:.4pt;margin-right:26.0pt;
     margin-bottom:0in;margin-left:5.45pt;margin-bottom:.0001pt;punctuation-wrap:
     simple;mso-line-break-override:restrictions'><span lang=EN-GB
     style='letter-spacing:-.05pt;mso-ansi-language:EN-GB'>The</span><span
     lang=EN-GB style='mso-ansi-language:EN-GB'> use<span style='letter-spacing:
     -.1pt'> </span>of<span style='letter-spacing:.05pt'> </span><span
     style='letter-spacing:-.05pt'>ACE inhibitors</span><span style='letter-spacing:
     -.1pt'> </span><span style='letter-spacing:-.05pt'>is</span> not<span
     style='letter-spacing:-.1pt'> </span><span style='letter-spacing:-.05pt'>recommended</span>
     <span style='letter-spacing:-.05pt'>during</span><span style='letter-spacing:
     -.15pt'> </span>the<span style='letter-spacing:-.1pt'> </span><span
     style='letter-spacing:-.05pt'>first</span><span style='letter-spacing:
     -.1pt'> </span><span style='letter-spacing:-.05pt'>trimester</span><span
     style='letter-spacing:.05pt'> </span>of<span style='letter-spacing:-.1pt'>
     </span><span style='letter-spacing:-.05pt'>pregnancy</span> <span
     style='letter-spacing:-.05pt'>(see</span><span style='letter-spacing:-.1pt'>
     </span><span style='letter-spacing:-.05pt'>section</span><span
     style='letter-spacing:2.95pt'> </span>4.4).<o:p></o:p></span></p>
     <p class=MsoBodyText style='margin-top:.05pt;margin-right:0in;margin-bottom:
     0in;margin-left:5.45pt;margin-bottom:.0001pt;punctuation-wrap:simple;
     mso-line-break-override:restrictions'><span lang=EN-GB style='letter-spacing:
     -.05pt;mso-ansi-language:EN-GB'>The</span><span lang=EN-GB
     style='mso-ansi-language:EN-GB'> use<span style='letter-spacing:-.1pt'> </span>of<span
     style='letter-spacing:.05pt'> </span><span style='letter-spacing:-.05pt'>ACE
     inhibitors</span><span style='letter-spacing:-.1pt'> </span><span
     style='letter-spacing:-.05pt'>is</span> <span style='letter-spacing:-.05pt'>contraindicated</span><span
     style='letter-spacing:-.15pt'> </span>in<span style='letter-spacing:-.15pt'>
     </span>the<span style='letter-spacing:-.1pt'> </span><span
     style='letter-spacing:-.05pt'>second</span> and<span style='letter-spacing:
     -.15pt'> </span><span style='letter-spacing:-.05pt'>third</span><span
     style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.05pt'>trimesters</span>
     <span style='letter-spacing:-.1pt'>(see</span> <span style='letter-spacing:
     -.05pt'>sections</span> <span style='letter-spacing:-.05pt'>4.3</span> and
     4.4).<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="626" height="58" src="file:///C:/Users/101166/AppData/Local/Temp/msohtmlclip1/01/clip_image002.png" /><!--[if mso & !supportInlineShapes & supportFields]><span
lang=EN-GB style='font-size:10.0pt;mso-ansi-language:EN-GB'><v:shape id="_x0000_i1026"
 type="#_x0000_t75" style='width:465.1pt;height:39.85pt'>
 <v:imagedata croptop="-1" cropbottom="1"/>
 <o:lock v:ext="edit" rotation="t" position="t"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p>Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded. Unless continued ACE inhibitor therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with ACE inhibitors should be stopped immediately, and, if appropriate, alternative therapy should be started.</p><p>Exposure to ACE inhibitor therapy during the second and third trimesters is known to induce human foetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia). (See section 5.3) Should exposure to ACE inhibitor have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended. Infants whose mothers have taken ACE inhibitors should be closely observed for hypotension (see sections 4.3 and 4.4).</p><p>&nbsp;</p><p><em>Linked to amlodipine</em></p><p><em>&nbsp;</em></p><p>The safety of amlodipine in human pregnancy has not been established.</p><p>In animal studies, reproductive toxicity was observed at high doses (see section 5.3).</p><p>Use in pregnancy is only recommended when there is no safer alternative and when the disease itself carries greater risk for the mother and foetus.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>&nbsp;</p><p>No information is available regarding the use of lisinopril during breast feeding. Amlodipine is excreted in human milk. The proportion of the maternal dose received by the infant has been estimated with an interquartile range of 3&ndash;7%, with a maximum of 15%. The effect of amlodipine on infants is unknown. Lisonorm is not recommended and alternative treatments with better established safety profiles during breast feeding are preferable, especially while nursing a newborn or preterm infant.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>No experience is available with the effect of lisinopril and amlodipine on fertility from adequately controlled clinical studies.</p><p>&nbsp;</p><p><em>Linked to amlodipine</em></p><p><em>&nbsp;</em></p><p>Reversible biochemical changes in the head of spermatozoa have been reported in some patients treated by calcium channel blockers. Clinical data are insufficient regarding the potential effect of amlodipine on fertility. In one rat study, adverse effects were found on male fertility (see section 5.3).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Linked to lisinopril</em></p><p>When driving vehicles or operating machines it should be taken into account that occasionally dizziness or tiredness may occur.</p><p>&nbsp;</p><p><em>Linked to amlodipine</em></p><p>Amlodipine can have minor or moderate influence on the ability to drive and use machines. If patients taking amlodipine suffer from dizziness, headache, fatigue or nausea the ability to react may be impaired. Caution is recommended especially at the start of treatment.</p><p>&nbsp;</p><p>According to the above Lisonorm may influence the ability to drive and operate machines (particularly during the initial period of treatment).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>During a controlled clinical study (n=195), the incidence of adverse reactions was not higher in subjects receiving both active substances concomitantly than in patients on monotherapy. Adverse reactions were consistent with those reported previously with amlodipine and/or lisinopril. Adverse reactions were usually mild, transient and rarely warranted the discontinuation of treatment. The most common adverse reactions with the combination were headache (8%), cough (5%), and dizziness (3%).</p><p>&nbsp;</p><p>Frequencies are defined as follows: Very common (&ge;1/10), Common (&ge;1/100 to &lt;1/10), Uncommon (&ge;1/1,000 to &lt;1/100), Rare (&ge;1/10,000 to &lt;1/1,000), Very rare (&lt;1/10,000), not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p>&nbsp;</p><p>The following adverse drug reactions (ADRs) have been reported during the treatment with lisinopril and amlodipine independently:</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System</strong><strong> </strong><strong>Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>ADRs</strong><strong> with lisinopril</strong></p></td><td style="vertical-align:top"><p><strong>ADRs</strong><strong> </strong><strong>with amlodipine</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic</strong></p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Decreases in haemoglobin,</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>system</strong><strong> </strong><strong>disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Decreases in haematocrit</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Bone marrow depression,</p></td><td style="vertical-align:top"><p>Thrombocytopenia,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Agranulocytosis (see section</p></td><td style="vertical-align:top"><p>Leukocytopenia</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>4.4), Leucopenia,</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Neutropenia,</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Thrombocytopenia,</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Haemolytic anaemia,</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anaemia, Lymphadenopathy</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune</strong><strong> system disorders</strong></p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Autoimmune disease</p></td><td style="vertical-align:top"><p>Allergic reactions</p></td></tr><tr><td style="vertical-align:top"><p><strong>Endocrine</strong><strong> disorders</strong></p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Syndrome of inappropriate antidiuretic hormone secretion (SIADH)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism</strong><strong> </strong><strong>and nutrition</strong><strong> </strong><strong>disorders</strong></p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Hypoglycaemia</p></td><td style="vertical-align:top"><p>Hyperglycaemia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric</strong><strong> disorders</strong></p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Mood altered, Sleep</p></td><td style="vertical-align:top"><p>Insomnia, Mood</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>disturbances, Hallucinations</p></td><td style="vertical-align:top"><p>changes (including</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>anxiety),</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Depression</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Mental confusion</p></td><td style="vertical-align:top"><p>Confusion</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Depressive symptoms</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous</strong><strong> system disorders</strong></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Dizziness, Headache</p></td><td style="vertical-align:top"><p>Somnolence,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dizziness, Headache,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(especially at the</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>beginning of the</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>treatment)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Vertigo, Paraesthesia,</p></td><td style="vertical-align:top"><p>Syncope, Tremor,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dysgeusia</p></td><td style="vertical-align:top"><p>Dysgeusia,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypoaesthesia,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Rare</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Olfactory disturbance</p></td><td style="vertical-align:top"><p>Paraesthesia</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Very rare</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Hypertonia, Peripheral</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>neuropathy</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Syncope</p></td><td style="vertical-align:top"><p>Extrapyramidal</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System</strong><strong> </strong><strong>Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>ADRs</strong><strong> with lisinopril</strong></p></td><td style="vertical-align:top"><p><strong>ADRs</strong><strong> with amlodipine</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>disorder</p></td></tr><tr><td style="vertical-align:top"><p><strong>Eye</strong><strong> disorders</strong></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Visual disturbances (including diplopia)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Ear</strong><strong> and labyrinth disorders</strong></p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Tinnitus</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac</strong><strong> disorders</strong></p></td><td style="vertical-align:top"><p>Common</p><p>&nbsp;</p><p>Uncommon</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Very rare</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Myocardial infarction possibly secondary to excessive hypotension in high risk patients (see section 4.4), Tachycardia, Palpitations</p></td><td style="vertical-align:top"><p>Palpitations</p><p>&nbsp;</p><p>Arrhythmia (including bradycardia, ventricular tachycardia and atrial fibrillation)</p><p>&nbsp;</p><p>&nbsp;</p><p>Myocardial infarction</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular</strong><strong> disorders</strong></p></td><td style="vertical-align:top"><p>Common Uncommon</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Very rare</p></td><td style="vertical-align:top"><p>Orthostatic effects (including hypotension)</p><p>&nbsp;</p><p>Cerebrovascular accident possibly secondary to excessive hypotension in high risk patients (see section 4.4), Raynaud&rsquo;s phenomenon</p></td><td style="vertical-align:top"><p>Flushing Hypotension</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Vasculitis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory,</strong><strong> thoracic and</strong></p><p><strong>mediastinal</strong><strong> </strong><strong>disorders</strong></p></td><td style="vertical-align:top"><p>Common</p><p>&nbsp;</p><p>Uncommon Very rare</p></td><td style="vertical-align:top"><p>Cough</p><p>&nbsp;</p><p>Rhinitis</p><p>&nbsp;</p><p>Bronchospasm, Alveolitis allergic/Eosinophilic pneumonia, Sinusitis</p></td><td style="vertical-align:top"><p>Dyspnoea Cough, Rhinitis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal</strong><strong> </strong><strong>disorders</strong></p></td><td style="vertical-align:top"><p>Common</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Uncommon</p><p>&nbsp;</p><p>&nbsp;</p><p>Rare Very rare</p></td><td style="vertical-align:top"><p>Diarrhoea, Vomiting</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Abdominal pain, Nausea, Indigestion</p><p>&nbsp;</p><p>Dry mouth</p><p>&nbsp;</p><p>Pancreatitis, Intestinal angioedema</p></td><td style="vertical-align:top"><p>Abdominal pain,</p><p>Nausea, Dyspepsia, Altered bowel habit (diarrhoea and constipation)</p><p>&nbsp;</p><p>Vomiting, Dry mouth</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Pancreatitis, Gastritis, Gingival hyperplasia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary</strong><strong> disorders</strong></p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Hepatitis &ndash; either hepatocellular or cholestatic, Jaundice and hepatic failure (see section 4.4)</p></td><td style="vertical-align:top"><p>Hepatitis, Jaundice, Hepatic enzyme increased**</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous</strong></p><p><strong>tissue</strong><strong> disorders</strong></p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Rash, Pruritus</p></td><td style="vertical-align:top"><p>Alopecia, Rash,</p><p>Exanthema, Purpura, Skin discolouration, Hyperhidrosis, Pruritus, Urticaria</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System</strong><strong> </strong><strong>Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>ADRs</strong><strong> with lisinopril</strong></p></td><td style="vertical-align:top"><p><strong>ADRs</strong><strong> with amlodipine</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Very rare</p></td><td style="vertical-align:top"><p>Psoriasis, Urticaria, Alopecia,</p><p>Hypersensitivity/angioneurotic oedema: angioneurotic oedema of the face, extremities, lips, tongue, glottis and/or larynx (see section 4.4)</p><p>&nbsp;</p><p>Toxic Epidermal Necrolysis, Stevens-Johnson Syndrome, Erythema multiforme, Pemphigus, Sweating, Cutaneous pseudolymphoma*</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Erythema multiforme, Angioedema, Exfoliative dermatitis, Stevens-Johnson syndrome, Quincke oedema, Photosensitivity</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal</strong><strong> </strong><strong>and</strong></p><p><strong>connective</strong><strong> tissue disorders</strong></p></td><td style="vertical-align:top"><p>Common</p><p>&nbsp;</p><p>&nbsp;</p><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Ankle swelling,</p><p>Muscle cramps</p><p>&nbsp;</p><p>Arthralgia, Myalgia, Back pain</p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal</strong><strong> </strong><strong>and urinary</strong></p><p><strong>disorders</strong></p></td><td style="vertical-align:top"><p>Common</p><p>&nbsp;</p><p>Uncommon</p><p>&nbsp;</p><p>Rare Very rare</p></td><td style="vertical-align:top"><p>Renal dysfunction</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Acute renal failure, Uraemia Oliguria/Anuria</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Micturition disorder, Nocturia, Increased urinary frequency</p></td></tr><tr><td style="vertical-align:top"><p><strong>Reproductive</strong><strong> </strong><strong>system</strong><strong> </strong><strong>and</strong><strong> </strong><strong>breast</strong><strong> </strong><strong>disorders</strong></p></td><td style="vertical-align:top"><p>Uncommon</p><p>&nbsp;</p><p>&nbsp;</p><p>Rare</p></td><td style="vertical-align:top"><p>Impotence</p><p>&nbsp;</p><p>&nbsp;</p><p>Gynaecomastia</p></td><td style="vertical-align:top"><p>Impotence, Gynaecomastia</p></td></tr><tr><td style="vertical-align:top"><p><strong>General</strong><strong> </strong><strong>disorders</strong><strong> and</strong></p><p><strong>administration</strong><strong> </strong><strong>site</strong><strong> </strong><strong>conditions</strong></p></td><td style="vertical-align:top"><p>Very</p><p>common Common Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Fatigue, Asthenia</p></td><td style="vertical-align:top"><p>Oedema</p><p>&nbsp;</p><p>Fatigue, Asthenia</p><p>&nbsp;</p><p>&nbsp;</p><p>Chest pain, Pain, Malaise</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top"><p>Uncommon</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Rare</p></td><td style="vertical-align:top"><p>Blood urea increased, Serum creatinine increased, Hyperkalaemia, Hepatic enzymes increased</p><p>&nbsp;</p><p>Serum bilirubin increased, Hyponatraemia</p></td><td style="vertical-align:top"><p>Weight increase, Weight decrease</p></td></tr></tbody></table><p>&nbsp;</p><p>*&nbsp; A symptom complex has been reported which may include one or more of the following: fever, vasculitis, myalgia, arthralgia/arthritis, a positive antinuclear antibodies (ANA), elevated red blood cell sedimentation rate (ESR), eosinophilia and leucocytosis, rash, photosensitivity or other dermatological manifestations may occur.</p><p>** Mostly consistent with cholestasis.</p><p>&nbsp;</p><p>Safety data from clinical studies suggest that lisinopril is generally well tolerated in hypertensive paediatric patients, and that the safety profile in this age group is comparable to that seen in adults.</p><p>&nbsp;</p><p><u>Reporting</u><u> </u><u>of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.</p><p>&nbsp;</p><p>To report any side effect(s):</p><p><strong>&nbsp;</strong></p><p><strong>Saudi Arabia:</strong></p><p>&middot; The National Pharmacovigilance Centre (NPC):</p><p>&nbsp;- SFDA Call Center: 19999</p><p>- E-mail: npc.drug@sfda.gov.sa</p><p>&nbsp;- Website: https://ade.sfda.gov.sa/</p><p><strong>&nbsp;</strong></p><p><strong>&middot; Other GCC States: </strong></p><p><strong>&nbsp;</strong>&nbsp;- Please contact the relevant competent</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No data are available on human overdosage with Lisonorm.</p><p>&nbsp;</p><p><em>Linked to lisinopril overdose:</em></p><p>Limited data are available for overdose in humans. Symptoms associated with overdosage of ACE inhibitors may include hypotension, circulatory shock, electrolyte disturbances, renal failure, hyperventilation, tachycardia, palpitations, bradycardia, dizziness, anxiety and cough.</p><p>The recommended treatment of overdose is intravenous infusion of normal saline solution. If hypotension occurs, the patient should be placed in the shock position. If available, treatment with angiotensin II infusion and/or intravenous catecholamines may also be considered. If ingestion is recent, take measures aimed at eliminating lisinopril (e.g., emesis, gastric lavage, administration of absorbents and sodium sulphate). Lisinopril may be removed from the general circulation by haemodialysis (see section 4.4). Pacemaker therapy is indicated for therapy-resistant bradycardia. Vital signs, serum electrolytes and creatinine concentrations should be monitored frequently.</p><p>&nbsp;</p><p><em>Linked to amlodipine overdose:</em></p><p>In humans experience with intentional overdose is limited.</p><p>&nbsp;</p><p>Symptoms</p><p>Available data suggest that gross overdosage could result in excessive peripheral vasodilatation and possibly reflex tachycardia. Marked and probably prolonged systemic hypotension up to and including shock with fatal outcome have been reported.</p><p>&nbsp;</p><p>Non-cardiogenic pulmonary oedema has rarely been reported as a consequence of amlodipine overdose that may manifest with a delayed onset (24-48&nbsp;hours post-ingestion) and require ventilatory support. Early resuscitative measures (including fluid overload) to maintain perfusion and cardiac output may be precipitating factors.</p><p>Treatment</p><p>Clinically significant hypotension due to amlodipine overdosage calls for active cardiovascular support including frequent monitoring of cardiac and respiratory function, elevation of extremities and attention to circulating fluid volume and urine output.</p><p>A vasoconstrictor may be helpful in restoring vascular tone and blood pressure, provided that there is no contraindication to its use. Intravenous calcium gluconate may be beneficial in reversing the effects of calcium channel blockade.Gastric lavage may be worthwhile in some cases. In healthy volunteers the use of charcoal up to 2 hours after administration of amlodipine 10 mg has been shown to reduce the absorption rate of amlodipine.</p><p>Since amlodipine is highly protein-bound, dialysis is not likely to be of benefit.</p><p>&nbsp;</p><p><em>Overdose</em><em> with Lisonorm </em>can result in excessive peripheral vasodilatation with marked hypotension, circulatory shock, electrolyte disturbances, renal failure, hyperventilation, tachycardia, palpitations, bradycardia, dizziness, anxiety, and cough. Symptomatic treatment (placing the patient in a supine position, monitoring &ndash; and when necessary, support &ndash; of cardiac and respiratory function, blood pressure, fluid and electrolyte balance and creatinine concentrations) is recommended. In case of serious hypotension, the lower extremities should be elevated, and when intravenous administration of fluid does not elicit sufficient response, supportive treatment added-on with administration of peripheral vasopressor agents may be necessary, unless contraindicated. If available, treatment with angiotensin II infusion may also be considered. Intravenous administration of calcium gluconate may be beneficial in reversing the effects of calcium channel blockade.</p><p>Lisinopril can be removed from the systemic circulation by haemodialysis. The use of high-flux polyacrylonitrile membranes should be avoided during dialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: ACE inhibitors and calcium channel blockers, lisinopril and amlodipine, ATC code: C09BB03</p><p>&nbsp;</p><p>Lisonorm is a fixed dose combination containing the active substances lisinopril and amlodipine. <u>Lisinopril</u></p><p><em>Mechanism </em><em>of action</em></p><p>Lisinopril is a peptidyl dipeptidase inhibitor. It inhibits the angiotensin-converting enzyme (ACE) that catalyses the conversion of angiotensin I to the vasoconstrictor peptide, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. Inhibition of ACE results in decreased concentrations of angiotensin II which results in decreased vasopressor activity and reduced aldosterone secretion. The latter decrease may result in an increase in serum potassium concentration.</p><p>&nbsp;</p><p><em>Pharmacodynamic</em><em> effects</em></p><p>Whilst the mechanism through which lisinopril lowers blood pressure is believed to be primarily suppression of the renin-angiotensin-aldosterone system, lisinopril is antihypertensive even in patients with low renin hypertension. ACE is identical to kininase II, an enzyme that degrades bradykinin.</p><p>Whether increased levels of bradykinin, a potent vasodilatory peptide, play a role in the therapeutic effects of lisinopril remains to be elucidated.</p><p>&nbsp;</p><p><em>Clinical</em><em> </em><em>efficacy</em><em> and safety</em></p><p>The effect of lisinopril on mortality and morbidity in heart failure has been studied by comparing a high dose (32.5 mg or 35 mg once daily) with a low dose (2.5 mg or 5 mg once daily). In a study of 3164 patients, with a median follow up period of 46 months for surviving patients, high dose lisinopril produced a 12% risk reduction in the combined endpoint of all-cause mortality and all-cause hospitalisation (p = 0.002) and an 8% risk reduction in all-cause mortality and cardiovascular hospitalisation (p = 0.036) compared with low dose. Risk reductions for all-cause mortality (8%; p = 0.128) and cardiovascular mortality (10%; p = 0.073) were observed. In a post-hoc analysis, the number of hospitalisations for heart failure was reduced by 24% (p=0.002) in patients treated with high-dose lisinopril compared with low dose. Symptomatic benefits were similar in patients treated with high and low doses of lisinopril.</p><p>&nbsp;</p><p>The results of the study showed that the overall adverse event profiles for patients treated with high or low dose lisinopril were similar in both nature and number. Predictable events resulting from ACE inhibition, such as hypotension or altered renal function, were manageable and rarely led to treatment withdrawal. Cough was less frequent in patients treated with high dose lisinopril compared with low dose.</p><p>&nbsp;</p><p>In the GISSI-3 trial, which used a 2x2 factorial design to compare the effects of lisinopril and glyceryl trinitrate given alone or in combination for 6 weeks versus control in 19,394 patients who were administered the treatment within 24 hours of an acute myocardial infarction, lisinopril produced a statistically significant risk reduction in mortality of 11% versus control (2p=0.03). The risk reduction with glyceryl trinitrate was not significant but the combination of lisinopril and glyceryl trinitrate produced a significant risk reduction in mortality of 17% versus control (2p=0.02). In the sub-groups of elderly (age &gt;70 years) and females, pre-defined as patients at high risk of mortality, significant benefit was observed for a combined endpoint of mortality and cardiac function. The combined endpoint for all patients, as well as the high-risk sub-groups, at 6 months also showed significant benefit for those treated with lisinopril or lisinopril plus glyceryl trinitrate for 6 weeks, indicating a prevention effect for lisinopril. As would be expected from any vasodilator treatment, increased incidences of hypotension and renal dysfunction were associated with lisinopril treatment but these</p><p>&nbsp;</p><p>were not associated with a proportional increase in mortality.</p><p>&nbsp;</p><p>In a double-blind, randomised, multicentre trial which compared lisinopril with a calcium channel blocker in 335 hypertensive Type 2 diabetes mellitus subjects with incipient nephropathy characterised by microalbuminuria, lisinopril 10 mg to 20 mg administered once daily for 12 months, reduced systolic/diastolic blood pressure by 13/10 mmHg and urinary albumin excretion rate by 40%. When compared with the calcium channel blocker, which produced a similar reduction in blood pressure, those treated with lisinopril showed a significantly greater reduction in urinary albumin excretion rate, providing evidence that the ACE inhibitory action of lisinopril reduced microalbuminuria by a direct mechanism on renal tissues in addition to its blood pressure lowering effect.</p><p>&nbsp;</p><p>Lisinopril treatment does not affect glycaemic control as shown by a lack of significant effect on levels of glycated haemoglobin (HbA1c).</p><p>&nbsp;</p><p><em>Renin-angiotensin</em><em> system (RAS)-acting agents</em></p><p>Two large randomised, controlled trials (ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)) have examined the use of the combination of an ACE-inhibitor with an angiotensin II receptor blocker.</p><p>ONTARGET was a study conducted in patients with a history of cardiovascular or cerebrovascular disease, or type 2 diabetes mellitus accompanied by evidence of end-organ damage.</p><p>VA NEPHRON-D was a study in patients with type 2 diabetes mellitus and diabetic nephropathy. These studies have shown no significant beneficial effect on renal and/or cardiovascular outcomes and mortality, while an increased risk of hyperkalaemia, acute kidney injury and/or hypotension as compared to monotherapy was observed.</p><p>Given their similar pharmacodynamic properties, these results are also relevant for other ACE- inhibitors and angiotensin II receptor blockers.</p><p>ACE-inhibitors and angiotensin II receptor blockers should therefore not be used concomitantly in patients with diabetic nephropathy.</p><p>ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2 diabetes mellitus and chronic kidney disease, cardiovascular disease, or both. The study was terminated early because of an increased risk of adverse outcomes. Cardiovascular death and stroke were both numerically more frequent in the aliskiren group than in the placebo group and adverse events and serious adverse events of interest (hyperkalaemia, hypotension and renal dysfunction) were more frequently reported in the aliskiren group than in the placebo group.</p><p>&nbsp;</p><p><em>Paediatric</em><em> population</em></p><p>In a clinical study involving 115 paediatric patients with hypertension, aged 6-16 years, patients who weighed less than 50 kg received either 0.625 mg, 2.5 mg or 20 mg of lisinopril once a day, and patients who weighed 50 kg or more received either 1.25 mg, 5 mg or 40 mg of lisinopril once a day. At the end of 2 weeks, lisinopril administered once daily lowered trough blood pressure in a dose- dependent manner with a consistent antihypertensive efficacy demonstrated at doses greater than</p><p>1.25 mg.</p><p>&nbsp;</p><p>This effect was confirmed in a withdrawal phase, where the diastolic pressure rose by about 9 mmHg more in patients randomized to placebo than it did in patients who were randomized to remain on the middle and high doses of lisinopril. The dose-dependent antihypertensive effect of lisinopril was consistent across several demographic subgroups: age, Tanner stage, gender, and race.</p><p>&nbsp;</p><p><u>Amlodipine</u></p><p>Amlodipine is a calcium ion influx inhibitor of the dihydropyridine group (slow channel blocker or calcium ion antagonist) and inhibits the transmembrane influx of calcium ions into cardiac and vascular smooth muscle.</p><p>&nbsp;</p><p>The mechanism of the antihypertensive action of amlodipine is due to a direct relaxant effect on vascular smooth muscle. The precise mechanism by which amlodipine relieves angina has not been fully determined but amlodipine reduces total ischaemic burden by the following two actions:</p><p>&nbsp;</p><p>1)&nbsp; Amlodipine dilates peripheral arterioles and thus, reduces the total peripheral resistance (afterload) against which the heart works. Since the heart rate remains stable, this unloading of the heart reduces myocardial energy consumption and oxygenrequirements.</p><p>&nbsp;</p><p>2)&nbsp; The mechanism of action of amlodipine also probably involves dilatation of the main coronary arteries and coronary arterioles, both in normal and ischaemic regions. This dilatation increases myocardial oxygen delivery in patients with coronary artery spasm (Prinzmetal&#39;s or variant angina).</p><p>&nbsp;</p><p>In patients with hypertension, once daily dosing provides clinically significant reductions of blood pressure in both the supine and standing positions throughout the 24 hour interval. Due to the slow onset of action, acute hypotension is not a feature of amlodipine administration.</p><p>&nbsp;</p><p>In patients with angina, once daily administration of amlodipine increases total exercise time, time to angina onset, and time to 1 mm ST segment depression, and decreases both angina attack frequency and glyceryl trinitrate tablet consumption.</p><p>&nbsp;</p><p>Amlodipine has not been associated with any adverse metabolic effects or changes in plasma lipids and is suitable for use in patients with asthma bronchiale, diabetes mellitus, and gout.</p><p>&nbsp;</p><p><u>Heart</u><u> </u><u>failure</u></p><p>Haemodynamic studies and exercise based controlled clinical trials in NYHA Class II-IV heart failure patients have shown that amlodipine did not lead to clinical deterioration as measured by exercise tolerance, left ventricular ejection fraction and clinical symptomatology.</p><p>A placebo controlled study (PRAISE) designed to evaluate patients in NYHA Class III-IV heart failure receiving digoxin, diuretics and ACE inhibitors has shown that amlodipine did not lead to an increase in risk of mortality or combined mortality and morbidity with heart failure.</p><p>In a follow-up, long term, placebo controlled study (PRAISE-2) of amlodipine in patients with NYHA III and IV heart failure without clinical symptoms or objective findings suggestive or underlying ischaemic disease, on stable doses of ACE inhibitors, digitalis, and diuretics, amlodipine had no effect on total cardiovascular mortality. In this same population amlodipine was associated with increased reports of pulmonary oedema.</p><p>&nbsp;</p><p><em>Antihypertensive</em><em> and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)</em></p><p>A randomized, double-blind, morbidity-mortality study called the Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) was performed to compare newer drug therapies: amlodipine 2.5-10 mg/day (calcium channel blocker) or lisinopril 10-40 mg/day (ACE- inhibitor) as first-line therapies to that of the thiazide-diuretic, chlorthalidone 12.5-25 mg/day in mild to moderate hypertension.</p><p>&nbsp;</p><p>A total of 33,357 hypertensive patients aged 55 or older were randomized and followed for a mean of</p><p>4.9 years. The patients had at least one additional CHD (coronary heart disease) risk factor, including: previous myocardial infarction or stroke (&gt; 6 months prior to enrollment) or documentation of other atherosclerotic CVD (cardiovascular disease) (overall 51.5%), type 2 diabetes (36.1%), HDL-C &lt; 35 mg/dl (11.6%), left ventricular hypertrophy diagnosed by electrocardiogram or echocardiography (20.9%), current cigarette smoking (21.9%).</p><p>&nbsp;</p><p>The primary endpoint was a composite of fatal CHD or non-fatal myocardial infarction. There was no significant difference in the primary endpoint between amlodipine-based therapy and chlorthalidone- based therapy: RR 0.98 95% CI [0.90-1.07] p=0.65. Among secondary endpoints, the incidence of heart failure (component of a composite combined cardiovascular endpoint) was significantly higher in the amlodipine group as compared to the chlorthalidone group (10.2% vs. 7.7%, RR 1.38, 95% CI [1.25-1.52] p&lt;0.001). However, there was no significant difference in all-cause mortality between</p><p>&nbsp;</p><p>amlodipine-based therapy and chlorthalidone-based therapy: RR 0.96 95% CI [0.89-1.02] p=0.20.</p><p>&nbsp;</p><p><u>Paediatric</u><u> </u><u>population</u><u> </u><u>(aged</u><u> </u><u>6 years and older)</u></p><p>In a study involving 268 children aged 6-17 years with predominantly secondary hypertension, comparison of a 2.5 mg dose and 5.0 mg dose of amlodipine with placebo, showed that both doses reduced systolic blood pressure significantly more than placebo. The difference between the two doses was not statistically significant.</p><p>The long-term effects of amlodipine on growth, puberty and general development have not been studied. The long-term efficacy of amlodipine on therapy in childhood to reduce cardiovascular morbidity and mortality in adulthood has also not been established.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Lisinopril</u></p><p>Lisinopril is an orally active non-sulphydryl-containing ACE inhibitor.</p><p>&nbsp;</p><p><em>Absorption</em></p><p>Following oral administration of lisinopril, peak serum concentrations occur within about 7 hours, although there was a trend to a small delay in time taken to reach peak serum concentrations in acute myocardial infarction patients. Based on urinary recovery, the mean extent of absorption of lisinopril is approximately 25% with inter-patient variability of 6-60% over the dose range studied (5-80 mg). The absolute bioavailability is reduced approximately 16% in patients with heart failure. Lisinopril absorption is not affected by the presence of food.</p><p>&nbsp;</p><p><em>Distribution</em></p><p>Lisinopril does not appear to be bound to serum proteins other than to circulating</p><p>angiotensin-converting enzyme (ACE). Studies in rats indicate that lisinopril crosses the blood-brain barrier poorly.</p><p>&nbsp;</p><p><em>Elimination</em></p><p>Lisinopril does not undergo metabolism and is excreted entirely unchanged into the urine. On multiple dosing, lisinopril has an effective half-life of accumulation of 12.6 hours. The clearance of lisinopril in healthy subjects is approximately 50 mL/min. Declining serum concentrations exhibit a prolonged terminal phase, which does not contribute to drug accumulation. This terminal phase probably represents saturable binding to ACE and is not proportional to dose.</p><p>&nbsp;</p><p><em><u>Pharmacokinetic</u></em><em><u> features in special populations</u></em></p><p><em>&nbsp;</em></p><p><em>Hepatic</em><em> impairment</em></p><p>Impairment of hepatic function in cirrhotic patients resulted in a decrease in lisinopril absorption (about 30% as determined by urinary recovery) but an increase in exposure (approximately 50%) compared to healthy subjects due to decreased clearence.</p><p>&nbsp;</p><p><em>Renal</em><em> </em><em>impairment</em></p><p>Impaired renal function decreases the elimination of lisinopril, which is excreted via the kidneys, but this decrease becomes clinically important only when the glomerular filtration rate is below</p><p>30 mL/min. In mild to moderate renal impairment (creatinine clearance 30 to 80 ml/min), mean AUC was increased by 13% only, while a 4.5- fold increase in mean AUC was observed in severe renal impairment (creatinine clearance 5- 30 mL/min). Lisinopril can be removed by dialysis. During 4 hours of haemodialysis, plasma lisinopril concentrations decreased on average by 60%, with a dialysis clearance between 40 and 55 mL/min.</p><p>&nbsp;</p><p><em>Heart</em><em> </em><em>failure</em></p><p>Patients with heart failure have a greater exposure of lisinopril when compared to healthy subjects (an increase in AUC on average of 125%), but based on the urinary recovery of lisinopril, there is a reduced absorption of approximately 16% compared to healthy subjects.</p><p>&nbsp;</p><p><em>Paediatric</em><em> population</em></p><p>The pharmacokinetic profile of lisinopril was studied in 29 paediatric hypertensive patients, aged between 6 and 16 years, with a GFR above 30 mL/min/1.73m2. After doses of 0.1 to 0.2 mg/kg, steady- state peak plasma concentrations of lisinopril occurred within 6 hours, and the extent of absorption based on urinary recovery was about 28%. These values are similar to those obtained previously in adults.</p><p>AUC and Cmax values&nbsp;in children in this study were consistent with those observed in adults.</p><p>&nbsp;</p><p><em>Elderly</em></p><p>Older patients have higher blood levels and higher values for the area under the plasma concentration- time curve (increased approximately 60 %) compared with younger subjects.</p><p>&nbsp;</p><p><u>Amlodipine</u></p><p>&nbsp;</p><p><em>Absorption,</em><em> distribution and plasma protein binding:</em></p><p>After oral administration of therapeutic doses amlodipine is well absorbed, producing peak plasma concentrations between 6-12 hours post dose. Absolute bioavailability has been estimated to be between 64 and 80%. The volume of distribution is approximately 21 L/kg. <em>In vitro </em>studies have shown that approximately 97.5% of circulating amlodipine is bound to plasma proteins.</p><p>The bioavailability of amlodipine is not affected by food intake.</p><p>&nbsp;</p><p><em>Biotransformation</em><em> and elimination</em></p><p>The terminal plasma elimination half-life is about 35-50 hours and is consistent with once daily dosing. Amlodipine is extensively metabolized by the liver to inactive metabolites with 10% of the parent compound and 60% of metabolites excreted in the urine.</p><p>&nbsp;</p><p><em><u>Pharmacokinetic</u></em><em><u> features in special populations</u></em></p><p><em>&nbsp;</em></p><p><em>Hepatic</em><em> impairment</em></p><p>Very limited clinical data are available regarding amlodipine administration in patients with hepatic impairment. Patients with hepatic insufficiency have decreased clearance of amlodipine resulting in a longer half-life and an increase in AUC of approximately 40-60%.</p><p>&nbsp;</p><p><em>Elderly</em></p><p>The time to reach peak plasma concentrations of amlodipine is similar in elderly and younger subjects. Amlodipine clearance tends to be decreased with resulting increases in AUC and elimination half-life in elderly patients.</p><p>Increases in AUC and elimination half-life in patients with congestive heart failure were as expected for the patient age group studied.</p><p>&nbsp;</p><p><em>Paediatric</em><em> population</em></p><p>A population PK study has been conducted in 74 hypertensive children aged from 1 to 17 years (with 34 patients aged 6 to 12 years and 28 patients aged 13 to 17 years) receiving amlodipine between 1.25 and 20 mg given either once or twice daily. In children 6 to 12 years and in adolescents 13-17 years of age the typical oral clearance (CL/F) was 22.5 and 27.4 L/h, respectively in males and 16.4 and 21.3 L/h, respectively in females. Large variability in exposure between individuals was observed. Data reported in children below 6 years is limited.</p><p>&nbsp;</p><p><u>Fixed dose combination</u></p><p>No pharmacokinetic interactions have been described between the active substances of Lisonorm. Pharmacokinetic parameters&nbsp;(AUC, Cmax,&nbsp;tmax, half-life) were not different from those observed after administration of the individual components separately.</p><p>&nbsp;</p><p>The gastrointestinal absorption of Lisonorm is not influenced by food.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical studies have not been conducted with the combination lisinopril-amlodipine.</p><p>&nbsp;</p><p><u>Lisinopril</u></p><p>Preclinical data reveal no special hazard for humans based on conventional studies of general pharmacology, repeated dose toxicity, genotoxicity and carcinogenic potential.</p><p>ACE inhibitors, as a class, have been shown to induce adverse effects on late foetal development, &nbsp;resulting in foetal death and congenital effects, in particular affecting the skull. Foetotoxicity, &nbsp;intrauterine growth retardation and patent ductus arteriosus have also been reported. These developmental anomalies are thought to be partly due to a direct action of ACE inhibitors on the foetal renin-angiotensin system and partly due to ischaemia resulting from maternal hypotension and decreases in foetal-placental blood flow and oxygen/nutrients delivery to the foetus.</p><p>&nbsp;</p><p><u>Amlodipine</u></p><p><em>Reproductive</em><em> </em><em>toxicology</em></p><p>Reproductive studies in rats and mice have shown delayed date of delivery, prolonged duration of labour and decreased pup survival at dosages approximately 50 times greater than the maximum recommended dosage for humans based on mg/kg.</p><p>&nbsp;</p><p><em>Impairment</em><em> </em><em>of </em><em>fertility</em></p><p>There was no effect on the fertility of rats treated with amlodipine (males for 64 days and females 14 days prior to mating) at doses up to 10 mg/kg/day (8 times* the maximum recommended human dose of 10 mg/day on a mg/m2&nbsp;basis). In another rat study in which male rats were treated with amlodipine besilate for 30 days at a dose comparable with the human dose based on mg/kg, decreased plasma follicle-stimulating hormone and testosterone were found as well as decreases in sperm density and in the number of mature spermatids and Sertoli cells.</p><p>&nbsp;</p><p><em>Carcinogenesis,</em><em> mutagenesis</em></p><p>Rats and mice treated with amlodipine in the diet for two years, at concentrations calculated to provide daily dosage levels of 0.5, 1.25, and 2.5 mg/kg/day showed no evidence of carcinogenicity. The highest dose (for mice, similar to, and for rats twice* the maximum recommended clinical dose of 10 mg/day on a mg/m2&nbsp;basis) was close to the maximum tolerated dose for mice but not for rats.</p><p>Mutagenicity studies revealed no active substance related effects at either the gene or chromosome levels.</p><p>&nbsp;</p><p>*Based on patient weight of 50 kg.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cellulose, microcrystalline</p><p>Sodium starch glycolate (Type A)</p><p>Magnesium stearate</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lisonorm10 mg/5 mg tablets: 2years

Lisonorm20 mg/10 mg tablets: 2 years

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C</p><p>Store in the original package in order to protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Lisonorm10</u></em><em><u> mg/5 mg tablets:</u></em></p><p>30 tablets in white, PVC/PE/PVDC/Aluminium blisters in a carton.</p><p>&nbsp;</p><p><em><u>Lisonorm20</u></em><em><u> mg/10 mg tablets:</u></em></p><p>30 tablets in white, PVC/PE/PVDC/Aluminium blisters in a carton.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements for disposal.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                AJA Pharmaceutical Industries Company, Ltd. 
Hail Industrial City MODON, Street No 32 
PO Box 6979, Hail 55414 
Kingdom of Saudi Arabia
Tel: +966 11 268 7900
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                July 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>